Q2 2024 --12-31 false 0000875657 2 2013 2014 2015 2016 2017 2018 2019 2020 2021 2022 2013 2014 2015 2019 2020 2021 2022 2005 2006 2007 2009 2011 2012 2013 2014 2015 0 0 0 3 0 0 0.21 0.21 0.03 0.21 0.21 0.21 0.03 0.21 0.10 0.10 0 0 0.10 0.10 00008756572024-01-012024-06-30 xbrli:pure 0000875657us-gaap:NonUsMember2023-01-012023-06-30 0000875657country:US2023-01-012023-06-30 iso4217:USD 00008756572023-01-012023-06-30 0000875657ulbi:CommunicationsSystemsSegmentMemberus-gaap:NonUsMember2023-01-012023-06-30 0000875657ulbi:CommunicationsSystemsSegmentMembercountry:US2023-01-012023-06-30 0000875657ulbi:CommunicationsSystemsSegmentMember2023-01-012023-06-30 0000875657ulbi:BatteryEnergyProductsSegmentMemberus-gaap:NonUsMember2023-01-012023-06-30 0000875657ulbi:BatteryEnergyProductsSegmentMembercountry:US2023-01-012023-06-30 0000875657ulbi:BatteryEnergyProductsSegmentMember2023-01-012023-06-30 0000875657us-gaap:NonUsMember2024-01-012024-06-30 0000875657country:US2024-01-012024-06-30 0000875657ulbi:CommunicationsSystemsSegmentMemberus-gaap:NonUsMember2024-01-012024-06-30 0000875657ulbi:CommunicationsSystemsSegmentMembercountry:US2024-01-012024-06-30 0000875657ulbi:CommunicationsSystemsSegmentMember2024-01-012024-06-30 0000875657ulbi:BatteryEnergyProductsSegmentMemberus-gaap:NonUsMember2024-01-012024-06-30 0000875657ulbi:BatteryEnergyProductsSegmentMembercountry:US2024-01-012024-06-30 0000875657ulbi:BatteryEnergyProductsSegmentMember2024-01-012024-06-30 0000875657us-gaap:NonUsMember2023-04-012023-06-30 0000875657country:US2023-04-012023-06-30 00008756572023-04-012023-06-30 0000875657ulbi:CommunicationsSystemsSegmentMemberus-gaap:NonUsMember2023-04-012023-06-30 0000875657ulbi:CommunicationsSystemsSegmentMembercountry:US2023-04-012023-06-30 0000875657ulbi:CommunicationsSystemsSegmentMember2023-04-012023-06-30 0000875657ulbi:BatteryEnergyProductsSegmentMemberus-gaap:NonUsMember2023-04-012023-06-30 0000875657ulbi:BatteryEnergyProductsSegmentMembercountry:US2023-04-012023-06-30 0000875657ulbi:BatteryEnergyProductsSegmentMember2023-04-012023-06-30 0000875657us-gaap:NonUsMember2024-04-012024-06-30 0000875657country:US2024-04-012024-06-30 00008756572024-04-012024-06-30 0000875657ulbi:CommunicationsSystemsSegmentMemberus-gaap:NonUsMember2024-04-012024-06-30 0000875657ulbi:CommunicationsSystemsSegmentMembercountry:US2024-04-012024-06-30 0000875657ulbi:CommunicationsSystemsSegmentMember2024-04-012024-06-30 0000875657ulbi:BatteryEnergyProductsSegmentMemberus-gaap:NonUsMember2024-04-012024-06-30 0000875657ulbi:BatteryEnergyProductsSegmentMembercountry:US2024-04-012024-06-30 0000875657ulbi:BatteryEnergyProductsSegmentMember2024-04-012024-06-30 0000875657ulbi:GovernmentDefenseMember2023-01-012023-06-30 0000875657ulbi:CommercialMember2023-01-012023-06-30 0000875657ulbi:GovernmentDefenseMemberulbi:CommunicationsSystemsSegmentMember2023-01-012023-06-30 0000875657ulbi:CommercialMemberulbi:CommunicationsSystemsSegmentMember2023-01-012023-06-30 0000875657ulbi:GovernmentDefenseMemberulbi:BatteryEnergyProductsSegmentMember2023-01-012023-06-30 0000875657ulbi:CommercialMemberulbi:BatteryEnergyProductsSegmentMember2023-01-012023-06-30 0000875657ulbi:GovernmentDefenseMember2024-01-012024-06-30 0000875657ulbi:CommercialMember2024-01-012024-06-30 0000875657ulbi:GovernmentDefenseMemberulbi:CommunicationsSystemsSegmentMember2024-01-012024-06-30 0000875657ulbi:CommercialMemberulbi:CommunicationsSystemsSegmentMember2024-01-012024-06-30 0000875657ulbi:GovernmentDefenseMemberulbi:BatteryEnergyProductsSegmentMember2024-01-012024-06-30 0000875657ulbi:CommercialMemberulbi:BatteryEnergyProductsSegmentMember2024-01-012024-06-30 0000875657ulbi:GovernmentDefenseMember2023-04-012023-06-30 0000875657ulbi:CommercialMember2023-04-012023-06-30 0000875657ulbi:GovernmentDefenseMemberulbi:CommunicationsSystemsSegmentMember2023-04-012023-06-30 0000875657ulbi:CommercialMemberulbi:CommunicationsSystemsSegmentMember2023-04-012023-06-30 0000875657ulbi:GovernmentDefenseMemberulbi:BatteryEnergyProductsSegmentMember2023-04-012023-06-30 0000875657ulbi:CommercialMemberulbi:BatteryEnergyProductsSegmentMember2023-04-012023-06-30 0000875657ulbi:GovernmentDefenseMember2024-04-012024-06-30 0000875657ulbi:CommercialMember2024-04-012024-06-30 0000875657ulbi:GovernmentDefenseMemberulbi:CommunicationsSystemsSegmentMember2024-04-012024-06-30 0000875657ulbi:CommercialMemberulbi:CommunicationsSystemsSegmentMember2024-04-012024-06-30 0000875657ulbi:GovernmentDefenseMemberulbi:BatteryEnergyProductsSegmentMember2024-04-012024-06-30 0000875657ulbi:CommercialMemberulbi:BatteryEnergyProductsSegmentMember2024-04-012024-06-30 0000875657us-gaap:CorporateMember2023-01-012023-06-30 0000875657us-gaap:CorporateMember2024-01-012024-06-30 0000875657us-gaap:CorporateMember2023-04-012023-06-30 0000875657us-gaap:CorporateMember2024-04-012024-06-30 0000875657us-gaap:OtherNoncurrentLiabilitiesMember2023-12-31 0000875657ulbi:AccruedExpensesAndOtherCurrentLiabilitiesMember2023-12-31 00008756572023-12-31 0000875657us-gaap:OtherNoncurrentLiabilitiesMember2024-06-30 0000875657ulbi:AccruedExpensesAndOtherCurrentLiabilitiesMember2024-06-30 00008756572024-06-30 0000875657ulbi:CertainCommunicationsSystemsProductsMember2024-01-012024-06-30 0000875657ulbi:CertainCommunicationsSystemsProductsMember2024-04-012024-06-30 utr:Y 0000875657ulbi:CertainCommunicationsSystemsProductsMembersrt:MaximumMember2024-01-012024-06-30 00008756572023-06-30 00008756572022-12-31 0000875657ulbi:CapitalAdditionPurchaseCommitmentsMember2024-01-012024-06-30 0000875657ulbi:AccruedExpensesAndOtherCurrentLiabilitesAndOtherNoncurrentLiabilitiesMember2024-06-30 0000875657ulbi:AccruedExpensesAndOtherCurrentLiabilitesAndOtherNoncurrentLiabilitiesMember2023-12-31 0000875657us-gaap:OtherNoncurrentAssetsMember2023-12-31 0000875657us-gaap:OtherNoncurrentAssetsMember2024-06-30 0000875657srt:MaximumMember2024-06-30 0000875657srt:MinimumMember2024-06-30 thunderdome:item 0000875657us-gaap:ForeignTaxJurisdictionOtherMember2024-01-012024-06-30 0000875657us-gaap:StateAndLocalJurisdictionMember2024-01-012024-06-30 0000875657us-gaap:DomesticCountryMemberus-gaap:InternalRevenueServiceIRSMember2024-01-012024-06-30 0000875657us-gaap:ForeignCountryMember2024-06-30 0000875657us-gaap:ForeignCountryMemberus-gaap:HerMajestysRevenueAndCustomsHMRCMember2024-06-30 0000875657us-gaap:DomesticCountryMemberus-gaap:InternalRevenueServiceIRSMember2023-12-31 0000875657us-gaap:RestrictedStockMember2023-06-30 0000875657us-gaap:RestrictedStockMember2024-06-30 0000875657us-gaap:RestrictedStockMemberulbi:The2014LongtermIncentivePlan2014Member2024-01-012024-06-30 iso4217:USDxbrli:shares xbrli:shares 0000875657us-gaap:EmployeeStockOptionMember2024-01-012024-06-30 0000875657us-gaap:EmployeeStockOptionMember2024-06-30 0000875657us-gaap:RestrictedStockMember2023-01-012023-06-30 0000875657us-gaap:RestrictedStockMember2024-01-012024-06-30 0000875657us-gaap:RestrictedStockMember2023-04-012023-06-30 0000875657us-gaap:RestrictedStockMember2024-04-012024-06-30 0000875657us-gaap:EmployeeStockOptionMember2023-01-012023-06-30 0000875657us-gaap:EmployeeStockOptionMember2023-04-012023-06-30 0000875657us-gaap:EmployeeStockOptionMember2024-04-012024-06-30 0000875657us-gaap:SellingGeneralAndAdministrativeExpensesMember2023-01-012023-06-30 0000875657us-gaap:SellingGeneralAndAdministrativeExpensesMember2024-01-012024-06-30 0000875657us-gaap:SellingGeneralAndAdministrativeExpensesMember2023-04-012023-06-30 0000875657us-gaap:SellingGeneralAndAdministrativeExpensesMember2024-04-012024-06-30 0000875657us-gaap:ResearchAndDevelopmentExpenseMember2023-01-012023-06-30 0000875657us-gaap:ResearchAndDevelopmentExpenseMember2024-01-012024-06-30 0000875657us-gaap:ResearchAndDevelopmentExpenseMember2023-04-012023-06-30 0000875657us-gaap:ResearchAndDevelopmentExpenseMember2024-04-012024-06-30 0000875657us-gaap:OtherIntangibleAssetsMember2023-12-31 0000875657us-gaap:TrademarksMember2023-12-31 0000875657us-gaap:TradeNamesMember2023-12-31 0000875657us-gaap:PatentedTechnologyMember2023-12-31 0000875657us-gaap:CustomerRelationshipsMember2023-12-31 0000875657us-gaap:OtherIntangibleAssetsMember2024-06-30 0000875657us-gaap:TrademarksMember2024-06-30 0000875657us-gaap:TradeNamesMember2024-06-30 0000875657us-gaap:PatentedTechnologyMember2024-06-30 0000875657us-gaap:CustomerRelationshipsMember2024-06-30 0000875657ulbi:CommunicationsSystemsSegmentMember2024-06-30 0000875657ulbi:BatteryEnergyProductsSegmentMember2024-06-30 0000875657ulbi:CommunicationsSystemsSegmentMember2023-12-31 0000875657ulbi:BatteryEnergyProductsSegmentMember2023-12-31 0000875657us-gaap:ConstructionInProgressMember2023-12-31 0000875657us-gaap:ConstructionInProgressMember2024-06-30 0000875657us-gaap:ComputerEquipmentMember2023-12-31 0000875657us-gaap:ComputerEquipmentMember2024-06-30 0000875657us-gaap:FurnitureAndFixturesMember2023-12-31 0000875657us-gaap:FurnitureAndFixturesMember2024-06-30 0000875657us-gaap:MachineryAndEquipmentMember2023-12-31 0000875657us-gaap:MachineryAndEquipmentMember2024-06-30 0000875657us-gaap:BuildingAndBuildingImprovementsMember2023-12-31 0000875657us-gaap:BuildingAndBuildingImprovementsMember2024-06-30 0000875657us-gaap:LandMember2023-12-31 0000875657us-gaap:LandMember2024-06-30 0000875657country:NL2024-06-30 0000875657country:NL2023-12-31 0000875657us-gaap:EmployeeStockOptionMember2023-01-012023-06-30 0000875657us-gaap:EmployeeStockOptionMember2024-01-012024-06-30 0000875657us-gaap:EmployeeStockOptionMember2023-04-012023-06-30 0000875657us-gaap:RevolvingCreditFacilityMemberulbi:AmendedCreditAgreementMember2024-06-30 0000875657us-gaap:RevolvingCreditFacilityMemberulbi:AmendedCreditAgreementMembersrt:MaximumMember2021-12-132021-12-13 0000875657us-gaap:RevolvingCreditFacilityMemberulbi:AmendedCreditAgreementMembersrt:MinimumMember2021-12-132021-12-13 0000875657us-gaap:RevolvingCreditFacilityMemberulbi:AmendedCreditAgreementMembersrt:MaximumMemberus-gaap:SecuredOvernightFinancingRateSofrOvernightIndexSwapRateMember2021-12-132021-12-13 0000875657us-gaap:RevolvingCreditFacilityMemberulbi:AmendedCreditAgreementMembersrt:MinimumMemberus-gaap:SecuredOvernightFinancingRateSofrOvernightIndexSwapRateMember2021-12-132021-12-13 0000875657us-gaap:RevolvingCreditFacilityMemberulbi:AmendedCreditAgreementMemberus-gaap:SecuredOvernightFinancingRateSofrOvernightIndexSwapRateMember2021-12-132021-12-13 0000875657us-gaap:RevolvingCreditFacilityMemberulbi:AmendedCreditAgreementMember2023-06-30 0000875657us-gaap:RevolvingCreditFacilityMemberulbi:AmendedCreditAgreementMember2022-12-31 0000875657ulbi:AmendedCreditAgreementMember2024-06-30 0000875657ulbi:LongtermDebtCurrentMaturitiesMemberulbi:TermLoanFacilityMemberulbi:AmendedCreditAgreementMember2024-06-30 0000875657us-gaap:RevolvingCreditFacilityMemberulbi:AmendedCreditAgreementMemberulbi:KeybankMember2021-12-13 0000875657ulbi:TermLoanFacilityMemberulbi:AmendedCreditAgreementMemberulbi:KeybankMember2021-12-13 0000875657ulbi:TermLoanFacilityMemberulbi:AmendedCreditAgreementMemberulbi:KeybankMember2021-12-132021-12-13 0000875657us-gaap:NoncontrollingInterestMember2024-06-30 0000875657us-gaap:TreasuryStockCommonMember2024-06-30 0000875657us-gaap:RetainedEarningsMember2024-06-30 0000875657us-gaap:AociIncludingPortionAttributableToNoncontrollingInterestMember2024-06-30 0000875657us-gaap:AdditionalPaidInCapitalMember2024-06-30 0000875657us-gaap:CommonStockMember2024-06-30 0000875657us-gaap:AociIncludingPortionAttributableToNoncontrollingInterestMember2024-04-012024-06-30 0000875657us-gaap:AdditionalPaidInCapitalMember2024-04-012024-06-30 0000875657us-gaap:TreasuryStockCommonMember2024-04-012024-06-30 0000875657us-gaap:CommonStockMember2024-04-012024-06-30 0000875657us-gaap:NoncontrollingInterestMember2024-04-012024-06-30 0000875657us-gaap:RetainedEarningsMember2024-04-012024-06-30 00008756572024-03-31 0000875657us-gaap:NoncontrollingInterestMember2024-03-31 0000875657us-gaap:TreasuryStockCommonMember2024-03-31 0000875657us-gaap:RetainedEarningsMember2024-03-31 0000875657us-gaap:AociIncludingPortionAttributableToNoncontrollingInterestMember2024-03-31 0000875657us-gaap:AdditionalPaidInCapitalMember2024-03-31 0000875657us-gaap:CommonStockMember2024-03-31 0000875657us-gaap:NoncontrollingInterestMember2023-06-30 0000875657us-gaap:TreasuryStockCommonMember2023-06-30 0000875657us-gaap:RetainedEarningsMember2023-06-30 0000875657us-gaap:AociIncludingPortionAttributableToNoncontrollingInterestMember2023-06-30 0000875657us-gaap:AdditionalPaidInCapitalMember2023-06-30 0000875657us-gaap:CommonStockMember2023-06-30 0000875657us-gaap:AociIncludingPortionAttributableToNoncontrollingInterestMember2023-04-012023-06-30 0000875657us-gaap:AdditionalPaidInCapitalMember2023-04-012023-06-30 0000875657us-gaap:TreasuryStockCommonMember2023-04-012023-06-30 0000875657us-gaap:CommonStockMember2023-04-012023-06-30 0000875657us-gaap:NoncontrollingInterestMember2023-04-012023-06-30 0000875657us-gaap:RetainedEarningsMember2023-04-012023-06-30 00008756572023-03-31 0000875657us-gaap:NoncontrollingInterestMember2023-03-31 0000875657us-gaap:TreasuryStockCommonMember2023-03-31 0000875657us-gaap:RetainedEarningsMember2023-03-31 0000875657us-gaap:AociIncludingPortionAttributableToNoncontrollingInterestMember2023-03-31 0000875657us-gaap:AdditionalPaidInCapitalMember2023-03-31 0000875657us-gaap:CommonStockMember2023-03-31 0000875657us-gaap:AociIncludingPortionAttributableToNoncontrollingInterestMember2024-01-012024-06-30 0000875657us-gaap:AdditionalPaidInCapitalMember2024-01-012024-06-30 0000875657us-gaap:TreasuryStockCommonMember2024-01-012024-06-30 0000875657us-gaap:CommonStockMember2024-01-012024-06-30 0000875657us-gaap:NoncontrollingInterestMember2024-01-012024-06-30 0000875657us-gaap:RetainedEarningsMember2024-01-012024-06-30 0000875657us-gaap:NoncontrollingInterestMember2023-12-31 0000875657us-gaap:TreasuryStockCommonMember2023-12-31 0000875657us-gaap:RetainedEarningsMember2023-12-31 0000875657us-gaap:AociIncludingPortionAttributableToNoncontrollingInterestMember2023-12-31 0000875657us-gaap:AdditionalPaidInCapitalMember2023-12-31 0000875657us-gaap:CommonStockMember2023-12-31 0000875657us-gaap:AociIncludingPortionAttributableToNoncontrollingInterestMember2023-01-012023-06-30 0000875657us-gaap:AdditionalPaidInCapitalMember2023-01-012023-06-30 0000875657us-gaap:TreasuryStockCommonMember2023-01-012023-06-30 0000875657us-gaap:CommonStockMember2023-01-012023-06-30 0000875657us-gaap:NoncontrollingInterestMember2023-01-012023-06-30 0000875657us-gaap:RetainedEarningsMember2023-01-012023-06-30 0000875657us-gaap:NoncontrollingInterestMember2022-12-31 0000875657us-gaap:TreasuryStockCommonMember2022-12-31 0000875657us-gaap:RetainedEarningsMember2022-12-31 0000875657us-gaap:AociIncludingPortionAttributableToNoncontrollingInterestMember2022-12-31 0000875657us-gaap:AdditionalPaidInCapitalMember2022-12-31 0000875657us-gaap:CommonStockMember2022-12-31 0000875657ulbi:TermLoanFacilityMember2023-01-012023-06-30 0000875657ulbi:TermLoanFacilityMember2024-01-012024-06-30 0000875657us-gaap:RevolvingCreditFacilityMember2023-01-012023-06-30 0000875657us-gaap:RevolvingCreditFacilityMember2024-01-012024-06-30 00008756572024-07-22
 

 

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

 

FORM 10-Q

 

(Mark One)                                    

QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934

For the quarterly period ended June 30, 2024

OR

TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934

For the transition period from                       to                      

 

Commission file number: 0-20852

ULTRALIFE CORPORATION

(Exact name of registrant as specified in its charter)

 

Delaware

(State or other jurisdiction of incorporation of organization)

 

2000 Technology Parkway Newark, New York 14513

(Address of principal executive offices) (Zip Code)

16-1387013

(I.R.S. Employer Identification No.)

 

(315) 332-7100 

(Registrant’s telephone number, including area code)

 

None

(Former name, former address and former fiscal year, if changed since last report)

 

Securities registered pursuant to Section 12(b) of the Act:

 

Common Stock, $0.10 par value per share

ULBI

NASDAQ

(Title of each class)

(Trading Symbol)

(Name of each exchange on which registered)

 

Indicate by check mark whether the registrant (1) has filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that the registrant was required to file such reports), and (2) has been subject to such filing requirements for the past 90 days. Yes ☒ No ☐

 

Indicate by check mark whether the registrant has submitted electronically every Interactive Data file required to be submitted pursuant to Rule 405 of Regulation S-T (§232.405 of this chapter) during the preceding 12 months (or for such shorter period that the registrant was required to submit such files). Yes ☒ No ☐

 

Indicate by check mark whether the registrant is a large accelerated filer, an accelerated filer, a non-accelerated filer, a smaller reporting company, or an emerging growth company. See the definitions of “large accelerated filer,” “accelerated filer,” “smaller reporting company,” and “emerging growth company” in Rule 12b-2 of the Exchange Act.

 

Large accelerated filer ☐

Accelerated filer ☐

  

Non-accelerated filer

Smaller reporting company

   
 

Emerging Growth Company

 

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐

 

Indicate by check mark whether the registrant is a shell company (as defined in Rule 12b-2 of the Exchange Act). Yes No☒

 

As of July 22, 2024, the registrant had 16,623,347 shares of common stock outstanding.

 



 

 

 

 

ULTRALIFE CORPORATION AND SUBSIDIARIES

 

INDEX

 

         

   

Page

PART I.

FINANCIAL INFORMATION

 
     

Item 1.

Consolidated Financial Statements (unaudited):

 
     
 

Consolidated Balance Sheets as of June 30, 2024 and December 31, 2023

1

     
 

Consolidated Statements of Income and Comprehensive Income for the Three and Six-Month Periods Ended June 30, 2024 and June 30, 2023

2

     
 

Consolidated Statements of Cash Flows for the Six-Month Periods Ended June 30, 2024 and June 30, 2023

3

     
 

Consolidated Statements of Changes in Stockholders’ Equity for the Three and Six-Month Periods Ended June 30, 2024 and June 30, 2023

4

     
 

Notes to Consolidated Financial Statements (unaudited)

5

     

Item 2.

Management’s Discussion and Analysis of Financial Condition and Results of Operations

17

     

Item 4.

Controls and Procedures

26

     

PART II.

OTHER INFORMATION

 
     

Item 6.

Exhibits

27

     
 

Signatures

28

 

 

 

 

PART I. FINANCIAL INFORMATION

 

Item 1. CONSOLIDATED FINANCIAL STATEMENTS

 

ULTRALIFE CORPORATION AND SUBSIDIARIES

CONSOLIDATED BALANCE SHEETS

(In Thousands except share amounts)

(Unaudited)

 

 

   

June 30,

2024

   

December 31,

2023

 
ASSETS                

Current assets:

               

Cash

  $ 6,690     $ 10,278  

Trade accounts receivable, net of allowance for expected credit losses of $296 and $300, respectively

    31,055       31,761  

Inventories, net

    41,392       42,215  

Prepaid expenses and other current assets

    4,650       5,949  

Total current assets

    83,787       90,203  

Property, plant and equipment, net

    20,281       21,117  

Goodwill

    37,510       37,571  

Other intangible assets, net

    14,646       15,107  

Deferred income taxes, net

    9,088       10,567  

Other noncurrent assets

    4,505       3,711  

Total assets

  $ 169,817     $ 178,276  
 LIABILITIES AND STOCKHOLDERS EQUITY                

Current liabilities:

               

Accounts payable

  $ 9,691     $ 11,336  

Current portion of long-term debt

    2,000       2,000  

Accrued compensation and related benefits

    2,312       3,115  

Accrued expenses and other current liabilities

    6,570       7,279  

Total current liabilities

    20,573       23,730  

Long-term debt, net

    9,978       23,624  

Deferred income taxes

    1,642       1,714  

Other noncurrent liabilities

    4,279       3,781  

Total liabilities

    36,472       52,849  
                 

Commitments and contingencies (Note 8)

           
                 

Stockholders’ equity:

               

Preferred stock – par value $.10 per share; authorized 1,000,000 shares; none issued

    -       -  

Common stock – par value $.10 per share; authorized 40,000,000 shares; issued – 21,059,461 shares at June 30, 2024 and 20,783,607 shares at December 31, 2023; outstanding – 16,623,347 shares at June 30, 2024 and 16,347,493 shares at December 31, 2023

    2,106       2,078  

Capital in excess of par value

    191,388       189,160  

Accumulated deficit

    (34,894 )     (40,754 )

Accumulated other comprehensive loss

    (3,895 )     (3,660 )

Treasury stock - at cost; 4,436,114 shares at June 30, 2024 and 4,436,114 shares at December 31, 2023

    (21,492 )     (21,492 )

Total Ultralife Corporation equity

    133,213       125,332  

Non-controlling interest

    132       95  

Total stockholders’ equity

    133,345       125,427  
                 

Total liabilities and stockholders’ equity

  $ 169,817     $ 178,276  

 

The accompanying notes are an integral part of these consolidated financial statements.

 

 

1

 

 

ULTRALIFE CORPORATION AND SUBSIDIARIES

CONSOLIDATED STATEMENTS OF INCOME AND COMPREHENSIVE INCOME

(In thousands except per share amounts)

(Unaudited)

 

   

Three-month period ended

   

Six-month period ended

 
   

June 30,

2024

   

June 30,

2023

   

June 30,

2024

   

June 30,

2023

 
                                 

Revenues

  $ 42,983     $ 42,692     $ 84,910     $ 74,608  

Cost of products sold

    31,420       32,104       61,877       56,584  

Gross profit

    11,563       10,588       23,033       18,024  
                                 

Operating expenses:

                               

Research and development

    1,997       1,778       3,753       3,810  

Selling, general and administrative

    5,649       5,145       11,300       10,523  

Total operating expenses

    7,646       6,923       15,053       14,333  
                                 

Operating income

    3,917       3,665       7,980       3,691  
                                 

Other (expense) income:

                               

Interest and financing expense

    (418 )     (440 )     (938 )     (864 )

Miscellaneous income

    347       1,498       411       1,428  

Total other (expense) income

    (71 )     1,058       (527 )     564  
                                 

Income before income taxes

    3,846       4,723       7,453       4,255  

Income tax provision

    853       1,375       1,556       1,242  
                                 

Net income

    2,993       3,348       5,897       3,013  
                                 

Net income attributable to non-controlling interest

    24       8       37       19  
                                 

Net income attributable to Ultralife Corporation

    2,969       3,340       5,860       2,994  
                                 

Other comprehensive loss:

                               

Foreign currency translation adjustments

    (3 )     (293 )     (235 )     (96 )
                                 

Comprehensive income attributable to Ultralife Corporation

  $ 2,966     $ 3,047     $ 5,625     $ 2,898  
                                 

Net income per share attributable to Ultralife common stockholders basic

  $ .18     $ .21     $ .36     $ .19  
                                 

Net income per share attributable to Ultralife common stockholders diluted

  $ .18     $ .21     $ .35     $ .19  
                                 

Weighted average shares outstanding basic

    16,568       16,141       16,482       16,138  

Potential common shares

    257       3       179       3  

Weighted average shares outstanding - diluted

    16,825       16,144       16,661       16,141  

 

The accompanying notes are an integral part of these consolidated financial statements.

 

2

 

 

ULTRALIFE CORPORATION AND SUBSIDIARIES

CONSOLIDATED STATEMENTS OF CASH FLOWS

(Dollars in Thousands)

(Unaudited)

 

   

Six-month period ended

 
   

June 30,

2024

   

June 30,

2023

 

OPERATING ACTIVITIES:

               

Net income

  $ 5,897     $ 3,013  
Adjustments to reconcile net income to net cash provided by operating activities:                

Depreciation

    1,529       1,522  

Amortization of intangible assets

    455       436  

Amortization of financing fees

    32       32  

Stock-based compensation

    320       293  

Deferred income taxes

    1,394       888  

Changes in operating assets and liabilities:

               

Accounts receivable

    654       (803 )

Inventories

    717       (4,882 )

Prepaid expenses and other assets

    404       (526 )

Accounts payable and other liabilities

    (2,558 )     413  

Net cash provided by operating activities

    8,844       386  
                 

INVESTING ACTIVITIES:

               

Purchases of property, plant and equipment

    (732 )     (1,013 )

Net cash used in investing activities

    (732 )     (1,013 )
                 

FINANCING ACTIVITIES:

               

(Payments) borrowings on revolving credit facility

    (12,679 )     4,300  

Payments on term loan facility

    (1,000 )     (1,000 )

Proceeds from exercise of stock options

    1,936       62  

Net cash (used in) provided by financing activities

    (11,743 )     3,362  
                 

Effect of exchange rate changes on cash

    43       (165 )
                 

(DECREASE) INCREASE IN CASH

    (3,588 )     2,570  
                 

Cash, Beginning of period

    10,278       5,713  

Cash, End of period

  $ 6,690     $ 8,283  

 

The accompanying notes are an integral part of these consolidated financial statements.

 

3

 

 

ULTRALIFE CORPORATION AND SUBSIDIARIES

CONSOLIDATED STATEMENTS OF CHANGES IN STOCKHOLDERS EQUITY

(In thousands except share amounts) (Unaudited)

 

                   

Capital

   

Accumulated

                                 
   

Common Stock

   

in Excess

   

Other

                   

Non-

         
   

Number of

           

of Par

   

Comprehensive

   

Accumulated

   

Treasury

   

Controlling

         
   

Shares

   

Amount

   

Value

   

Income (Loss)

   

Deficit

   

Stock

   

Interest

   

Total

 
                                                                 

Balance December 31, 2022

    20,570,710     $ 2,057     $ 187,405     $ (3,750 )   $ (47,951 )   $ (21,484 )   $ 126     $ 116,403  

Net income

                                    2,994               19       3,013  

Stock option exercises

    15,335       2       60                       -               62  

Stock-based compensation – stock options

                    291                                       291  

Stock-based compensation - restricted stock

                    2                                       2  

Foreign currency translation adjustments

                            (96 )                             (96 )

Balance June 30, 2023

    20,586,045     $ 2,059     $ 187,758     $ (3,846 )   $ (44,957 )   $ (21,484 )   $ 145     $ 119,675  
                                                                 

Balance December 31, 2023

    20,783,607     $ 2,078     $ 189,160     $ (3,660 )   $ (40,754 )   $ (21,492 )   $ 95     $ 125,427  

Net income

                                    5,860               37       5,897  

Stock option exercises

    275,854       28       1,908                       -               1,936  

Stock-based compensation – stock options

                    308                                       308  

Stock-based compensation -restricted stock

                    12                                       12  

Foreign currency translation adjustments

                            (235 )                             (235 )

Balance June 30, 2024

    21,059,461     $ 2,106     $ 191,388     $ (3,895 )   $ (34,894 )   $ (21,492 )   $ 132     $ 133,345  
                                                                 

Balance March 31, 2023

    20,570,710     $ 2,057     $ 187,544     $ (3,553 )   $ (48,297 )   $ (21,484 )   $ 137     $ 116,404  

Net income

                                    3,340               8       3,348  

Stock option exercises

    15,335       2       60                       -               62  

Stock-based compensation – stock options

                    153                                       153  

Stock-based compensation -restricted stock

                    1                                       1  

Foreign currency translation adjustments

                            (293 )                             (293 )

Balance June 30, 2023

    20,586,045     $ 2,059     $ 187,758     $ (3,846 )   $ (44,957 )   $ (21,484 )   $ 145     $ 119,675  
                                                                 

Balance March 31, 2024

    20,887,446     $ 2,089     $ 189,995     $ (3,892 )   $ (37,863 )   $ (21,492 )   $ 108     $ 128,945  

Net income

                                    2,969               24       2,993  

Stock option exercises

    172,015       17       1,234                       -               1,251  

Stock-based compensation – stock options

                    152                                       152  

Stock-based compensation -restricted stock

                    7                                       7  

Foreign currency translation adjustments

                            (3 )                             (3 )

Balance June 30, 2024

    21,059,461     $ 2,106     $ 191,388     $ (3,895 )   $ (34,894 )   $ (21,492 )   $ 132     $ 133,345  

 

The accompanying notes are an integral part of these consolidated financial statements.

 

4

 

ULTRALIFE CORPORATION

NOTES TO CONSOLIDATED FINANCIAL STATEMENTS

(In thousands except share and per share amounts)

(Unaudited)

 

 

1.

BASIS OF PRESENTATION

 

The accompanying unaudited consolidated financial statements of Ultralife Corporation and its subsidiaries (the “Company” or “Ultralife”) have been prepared in accordance with generally accepted accounting principles in the United States of America (“GAAP”) for interim financial information and with the instructions to Rule 8-03 of Regulation S-X. Accordingly, they do not include all the information and notes for complete financial statements. In the opinion of management, all adjustments (consisting of normal recurring accruals and adjustments) considered necessary for a fair presentation of the consolidated financial statements have been included. Results for interim periods should not be considered indicative of results to be expected for a full year. Reference should be made to the consolidated financial statements and related notes thereto contained in our Form 10-K for the year ended December 31, 2023.

 

The December 31, 2023 consolidated balance sheet information referenced herein was derived from audited financial statements but does not include all disclosures required by GAAP.

 

Certain items previously reported in specific financial statement captions have been reclassified to conform to the current presentation.

 

 

Recent Accounting Guidance Not Yet Adopted

 

In December 2023, the Financial Accounting Standards Board (“FASB”) issued ASU 2023-09 "Income Taxes (Topics 740): Improvements to Income Tax Disclosures" to expand the disclosure requirements for income taxes, specifically related to the rate reconciliation and income taxes paid. ASU 2023-09 is effective for our annual periods beginning January 1, 2025, with early adoption permitted. We are currently evaluating the potential effect that the updated standard will have on our financial statement disclosures.

 

 

 

2.

DEBT

 

On December 13, 2021, Ultralife, Southwest Electronic Energy Corporation, a Texas corporation and wholly owned subsidiary of Ultralife (“SWE”), CLB, INC., a Texas corporation and wholly owned subsidiary of SWE (“CLB”), Ultralife Excell Holding Corp., a Delaware corporation and wholly owned subsidiary of Ultralife (“UEHC”), Ultralife Canada Holding Corp., a Delaware corporation and wholly owned subsidiary of UEHC (“UCHC”), and Excell Battery Corporation USA, a Texas corporation and wholly owned subsidiary of UEHC (“Excell USA”), as borrowers, entered into the Second Amendment Agreement with KeyBank National Association (“KeyBank” or the “Bank”), as lender and administrative agent, to amend the Credit and Security Agreement dated May 31, 2017 as amended by the First Amendment Agreement by and among Ultralife, SWE, CLB and KeyBank dated May 1, 2019 (the “Credit Agreement”). On November 28, 2022, Ultralife, SWE, CLB, UEHC, UCHC, Excell USA, and Excell Battery Canada ULC, a British Columbia unlimited liability corporation and wholly owned subsidiary of UCHC (“Excell Canada”), entered into that certain Third Amendment Agreement with KeyBank, to further amend the Credit Agreement to, among other things, facilitate the joinder of Excell Canada as a guarantor under the Credit Agreement and to replace the LIBOR benchmark thereunder with the Secured Overnight Financing Rate or “SOFR” (the “Third Amendment Agreement”). On June 30, 2024, Ultralife, SWE, CLB, UEHC, Excell USA and Excell Canada entered into that certain Fourth Amendment Agreement with KeyBank to extend the period under which loans may be requested by the Company under the Credit Agreement to May 30, 2028, to increase the “Applicable Margin” used in the calculation of the rate at which interest accrues on outstanding indebtedness under the Credit Agreement and to increase the fee payable on the average daily unused availability under the $30,000 senior secured revolving credit facility (the “Revolving Credit Facility”) which is made available to the Company under the Credit Agreement (the “Fourth Amendment Agreement”, and together with the Third Amendment Agreement, the Second Amendment Agreement and the Credit Agreement, the “Amended Credit Agreement”).

 

The Amended Credit Agreement, among other things, provides for a 5-year, $10,000 senior secured term loan (the “Term Loan Facility”) and extends the term of the Revolving Credit Facility through May 30, 2028. Up to six months prior to May 30, 2028, the Revolving Credit Facility may be increased to $50,000 with the Bank’s concurrence.

 

5

 

As of June 30, 2024, the Company had $5,167 outstanding principal on the Term Loan Facility, $2,000 of which is included in current portion of long-term debt on the balance sheet, and $6,902 outstanding on the Revolving Credit Facility. As of June 30, 2024, total unamortized debt issuance costs of $91, including placement, renewal and legal fees associated with the Amended Credit Agreement, are classified as a reduction of long-term debt on the balance sheet. Debt issuance costs are amortized to interest expense over the term of the Amended Credit Facilities.

 

The remaining availability under the Revolving Credit Facility is subject to certain borrowing base limits based on trade receivables and inventories.

 

The Company is required to repay the borrowings under the Term Loan Facility in equal consecutive monthly payments commencing on February 1, 2022, in arrears, together with applicable interest. All unpaid principal and accrued and unpaid interest with respect to the Term Loan Facility is due and payable in full on January 1, 2027. All unpaid principal and accrued and unpaid interest with respect to the Revolving Credit Facility is due and payable in full on May 30, 2028. The Company may voluntarily prepay principal amounts outstanding at any time subject to certain restrictions.

 

In addition to the customary affirmative and negative covenants, the Company must maintain a consolidated senior leverage ratio, as defined in the Amended Credit Agreement, of equal to or less than 3.5 to 1.0 for the fiscal quarters ending December 31, 2022 and March 31, 2023, and equal to or less than 3.0 to 1.0 for the fiscal quarters ending June 30, 2023 and thereafter. The Company was in full compliance with its covenants under the Amended Credit Agreement as of June 30, 2024.

 

Borrowings under the Amended Credit Facilities are secured by substantially all the assets of the Company and its subsidiaries.

 

Under the Amended Credit Agreement, interest accrues on outstanding indebtedness under the Amended Credit Facilities at the Daily Simple SOFR Rate, plus an index spread adjustment of 0.10%, plus the applicable margin. Upon the effectiveness of the Fourth Amendment Agreement, the applicable margin ranges from 210 to 240 basis points and is determined based on the Company’s senior leverage ratio.

 

In addition, the Company must pay a fee of 0.20% to 0.30% based on the average daily unused availability under the Revolving Credit Facility.

 

Payments must be made by the Company to the extent borrowings exceed the maximum amount then permitted to be drawn on the Amended Credit Facilities and from the proceeds of certain transactions. Upon the occurrence of an event of default, the outstanding obligations may be accelerated, and the Bank will have other customary remedies including resort to the security interest the Company provided to the Bank.

 

Future minimum principal repayment obligations on our Amended Credit Facilities as of June 30, 2024 are as follows:

 

2024

 

$

1,000  

2025

    2,000  

2026

    2,000  

2027

    167  

2028

    6,902  

Total

  $ 12,069  

 

6

 

 

3.

EARNINGS PER SHARE

 

Basic earnings (loss) per share (“EPS”) is computed by dividing net income (loss) attributable to Ultralife by the weighted average shares outstanding during the period. Diluted EPS includes the dilutive effect of securities, if any, and is calculated using the treasury stock method.

 

For the three-month period ended June 30, 2024, there were 873,898 outstanding stock options and 5,229 unvested restricted stock awards included in the calculation of diluted weighted average shares outstanding, as such securities were dilutive, resulting in 257,068 potential common shares included in the calculation of diluted EPS. For the comparable three-month period ended June 30, 2023, 4,166 outstanding stock options and 2,500 unvested restricted stock awards were included in the calculation of diluted weighted average shares outstanding, as such securities were dilutive, resulting in 2,334 potential common shares included in the calculation of diluted EPS. For the three-month period ended June 30, 2023, there were 1,289,862 outstanding stock options not included in the calculation of diluted weighted average shares outstanding as the effect would be anti-dilutive.

 

For the six-month period ended June 30, 2024, there were 795,898 outstanding stock options and 5,229 unvested restricted stock awards included in the calculation of diluted weighted average shares outstanding, resulting in 179,112 potential common shares included in the calculation of diluted EPS. For the comparable six-month period ended June 30, 2023, there were no outstanding stock options and 2,500 unvested restricted stock awards included in the calculation of diluted weighted average shares outstanding, resulting in 2,157 potential common shares included in the calculation of diluted EPS. There were 78,000 and 1,294,028 outstanding stock options for the six-month periods ended June 30, 2024 and 2023, respectively, not included in the calculation of diluted weighted average shares outstanding as the effect would be anti-dilutive.

 

 

 

4.

SUPPLEMENTAL BALANCE SHEET INFORMATION

 

Fair Value Measurements and Disclosures

 

The fair value of financial instruments approximated their carrying values at June 30, 2024 and December 31, 2023. The fair value of cash, accounts receivable, accounts payable, accrued liabilities, and the current portion of long-term debt approximates carrying value due to the short-term nature of these instruments.

 

Cash

 

The composition of the Company’s cash was as follows:

 

   

June 30,

   

December 31,

 
   

2024

   

2023

 

Cash

  $ 6,690     $ 10,196  

Restricted cash

    -       82  

Total

  $ 6,690     $ 10,278  

 

As December 31, 2023, restricted cash of $82 represented euro-denominated deposits withheld by the Dutch tax authorities and third-party VAT representatives in connection with a previously utilized logistics arrangement in the Netherlands. During the period ended June 30, 2024, the deposits were returned to the Company and no longer restricted. As of June 30, 2024, there was no cash classified as restricted cash. Restricted cash as of December 31, 2023 is included as a component of the cash balance for purposes of the consolidated statements of cash flows.

 

7

 

Inventories, Net

 

Inventories are stated at the lower of cost or net realizable value, net of obsolescence reserves, with cost determined under the first-in, first-out (FIFO) method. The composition of inventories, net was:

 

   

June 30,

   

December 31,

 
   

2024

   

2023

 

Raw materials

  $ 29,848     $ 29,098  

Work in process

    3,185       3,187  

Finished goods

    8,359       9,930  

Total

  $ 41,392     $ 42,215  

 

Property, Plant and Equipment, Net

 

Major classes of property, plant and equipment consisted of the following:

 

   

June 30,

   

December 31,

 
   

2024

   

2023

 

Land

  $ 1,273     $ 1,273  

Buildings and leasehold improvements

    16,064       15,998  

Machinery and equipment

    57,494       57,584  

Furniture and fixtures

    2,809       2,845  

Computer hardware and software

    7,816       7,868  

Construction in process

    1,846       2,033  
      87,302       87,601  

Less: Accumulated depreciation

    (67,021 )     (66,484 )

Property, plant and equipment, net

  $ 20,281     $ 21,117  

 

 

Depreciation expense for property, plant and equipment was as follows:

 

    Three-month period ended    

Six-month period ended

 
   

June 30,

   

June 30,

   

June 30,

   

June 30,

 
   

2024

   

2023

   

2024

   

2023

 

Depreciation expense

  $ 789     $ 760     $ 1,529     $ 1,522  

 

 

Goodwill

 

The following table summarizes the goodwill activity by segment for the six-month period ended June 30, 2024.

 

    Battery &

Energy

   

Communications

         
   

Products

   

Systems

   

Total

 

Balance – December 31, 2023

  $ 26,078     $ 11,493     $ 37,571  

Effect of foreign currency translation

    (61 )     -       (61 )

Balance – June 30, 2024

  $ 26,017     $ 11,493     $ 37,510  

 

8

 

Other Intangible Assets, Net

 

The composition of other intangible assets was:

 

   

at June 30, 2024

 
           

Accumulated

         
   

Cost

   

Amortization

   

Net

 

Customer relationships

  $ 13,087     $ 6,956     $ 6,131  

Patents and technology

    5,603       5,378       225  

Trade names

    4,647       703       3,944  

Trademarks

    3,399       -       3,399  

Other

    1,500       553       947  

Total other intangible assets

  $ 28,236     $ 13,590     $ 14,646  

 

 

   

at December 31, 2023

 
           

Accumulated

         
   

Cost

   

Amortization

   

Net

 

Customer relationships

  $ 13,092     $ 6,656     $ 6,436  

Patents and technology

    5,606       5,322       284  

Trade names

    4,647       647       4,000  

Trademarks

    3,402       -       3,402  

Other

    1,500       515       985  

Total other intangible assets

  $ 28,247     $ 13,140     $ 15,107  

 

 

The change in the cost of total intangible assets from December 31, 2023 to June 30, 2024 is the effect of foreign currency translations.

 

Amortization expense for other intangible assets was as follows:

 

   

Three-month period ended

   

Six-month period ended

 
   

June 30,

   

June 30,

   

June 30,

   

June 30,

 
   

2024

   

2023

   

2024

   

2023

 

Amortization included in:

                               

Selling, general and administrative

  $ 202     $ 203     $ 405     $ 388  

Research and development

    25       24       50       48  

Total amortization expense

  $ 227     $ 227     $ 455     $ 436  

 

9

 

 

5.

STOCK-BASED COMPENSATION

 

We recorded non-cash stock compensation expense in each period as follows:

 

   

Three-month period ended

   

Six-month period ended

 
   

June 30,

   

June 30,

   

June 30,

   

June 30,

 
   

2024

   

2023

   

2024

   

2023

 

Stock options

  $ 152     $ 153     $ 308     $ 291  

Restricted stock

    7       1       12       2  

Total

  $ 159     $ 154     $ 320     $ 293  

 

We have stock options outstanding from various stock-based employee compensation plans for which we record compensation cost relating to share-based payment transactions in our financial statements. As of June 30, 2024, there was $545 of total unrecognized compensation cost related to outstanding stock options, which is expected to be recognized over a weighted average period of 1.0 years.

 

The following table summarizes stock option activity for the six-month period ended June 30, 2024:

 

   

Number of

Shares

   

Weighted

Average

Exercise

Price

   

Weighted

Average

Remaining Contractual

Term (years)

   

Aggregate

Intrinsic

Value

 

Outstanding at January 1, 2024

    1,250,595     $ 7.10                  

Granted

    3,460       6.84                  

Exercised

    (288,675 )     7.10                  

Forfeited or expired

    (91,482 )   $ 8.79                  

Outstanding at June 30, 2024

    873,898     $ 6.92       4.34     $ 3,231  

Vested and expected to vest at June 30, 2024

    775,281     $ 7.00       4.18     $ 2,805  

Exercisable at June 30, 2024

    417,867     $ 7.56       2.87     $ 1,277  

 

Cash received from stock option exercises under our stock-based compensation plans for the three-month periods ended June 30, 2024 and June 30, 2023 was $1,251 and $62, respectively. Cash received from stock option exercises under our stock-based compensation plans for the six-month periods ended June 30, 2024 and June 30, 2023 was $1,936 and $62, respectively.

 

Restricted stock awards vest in equal annual installments over three (3) years. Unrecognized compensation cost related to unvested restricted shares at June 30, 2024 and June 30, 2023, respectively, was $25 and $1.

 

10

 

 

6.

INCOME TAXES

 

Our effective tax rate for the six-month periods ended June 30, 2024 and June 30, 2023 was 20.9% and 29.2%, respectively. The period-over-period change was primarily attributable to the geographic mix of our operating results and the larger impact of discrete adjustments for stock option exercises in the current year.

 

As of December 31, 2023, we have domestic net operating loss (“NOL”) carryforwards of $27,200, which expire 2031 through 2035, and domestic tax credits of $2,900, which expire 2028 through 2043, available to reduce future taxable income. As of June 30, 2024, management has concluded it is more likely than not that these domestic NOL and credit carryforwards will be fully utilized.

 

As of June 30, 2024, for certain past operations in the U.K., we continue to report a valuation allowance for NOL carryforwards of approximately $9,800, nearly all of which can be carried forward indefinitely. Utilization of the net operating losses may be limited due to the change in the past U.K. operation and cannot currently be used to reduce taxable income at our other U.K. subsidiary, Accutronics Ltd. There are no other deferred tax assets related to the past U.K. operations.

 

As of June 30, 2024, we have not recognized a valuation allowance against our other foreign deferred tax assets, as realization is considered to be more likely than not.

 

As of June 30, 2024, the Company maintains its assertion that all foreign earnings will be indefinitely reinvested in those operations, other than earnings generated in the U.K.

 

There were no unrecognized tax benefits related to uncertain tax positions at June 30, 2024 and December 31, 2023.

 

As a result of our operations, we file income tax returns in various jurisdictions including U.S. federal, U.S. state and foreign jurisdictions. We are routinely subject to examination by taxing authorities in these various jurisdictions. Our U.S. tax matters for 2020 thru 2022 remain subject to IRS examination. Our U.S. tax matters for 2001-2002, 2005-2007, 2009, and 2011-2015 also remain subject to IRS examination due to the remaining availability of net operating loss carryforwards generated in those years. Our U.S. tax matters for 2013 thru 2022 remain subject to examination by various state and local tax jurisdictions. Our tax matters for the years 2013 thru 2022 remain subject to examination by the respective foreign tax jurisdiction authorities.

 

 

 

7.

OPERATING LEASES

 

The Company has operating leases predominantly for operating facilities. As of June 30, 2024, the remaining lease terms on our operating leases range from approximately less than one (1) year to seven (7) years. Lease terms include renewal options reasonably certain of exercise. There is no transfer of title or option to purchase the leased assets upon expiration. There are no residual value guarantees or material restrictive covenants.

 

The components of lease expense for the current and prior-year comparative periods were as follows:

 

   

Three months ended

   

Six months ended

 
   

June 30, 2024

   

June 30, 2023

   

June 30, 2024

   

June 30, 2023

 

Operating lease cost

  $ 268     $ 239     $ 530     $ 480  

Variable lease cost

    24       29       52       57  

Total lease cost

  $ 292     $ 268     $ 582     $ 537  

 

11

 

Supplemental cash flow information related to leases was as follows:

 

   

Six-month period ended June 30,

 
   

2024

   

2023

 

Cash paid for amounts included in the measurement of lease liabilities:

               

Operating cash flows from operating leases

  $ 568     $ 494  

Right-of-use assets obtained in exchange for lease liabilities:

  $ 1,391     $ 310  

 

Supplemental consolidated balance sheet information related to leases was as follows:

 

 

Balance sheet classification

 

June 30,

2024

   

December 31,

2023

 

Assets:

                 

Operating lease right-of-use asset

Other noncurrent assets

  $ 4,325     $ 3,589  
                   

Liabilities:

                 

Current operating lease liability

Accrued expenses and other current liabilities

  $ 1,017     $ 894  

Operating lease liability, net of current portion

Other noncurrent liabilities

    3,285       2,644  

Total operating lease liability

  $ 4,302     $ 3,538  
                   

Weighted-average remaining lease term (years)

    5.1       5.3  
                   

Weighted-average discount rate

    6.8 %     4.5 %

 

Future minimum lease payments as of June 30, 2024 are as follows:

 

Maturity of operating lease liabilities

       

2024

  $ 539  

2025

    1,016  

2026

    942  

2027

    969  

2028

    977  

Thereafter

    624  

Total lease payments

    5,067  

Less: Imputed interest

    (765 )

Present value of remaining lease payments

  $ 4,302  

 

12

 

 

8.

COMMITMENTS AND CONTINGENCIES

 

Purchase Commitments

 

As of June 30, 2024, we have made commitments to purchase approximately $779 of production machinery and equipment.

 

Product Warranties

 

We estimate future warranty costs to be incurred for product failure rates, material usage and service costs in the development of our warranty obligations. Estimated future costs are based on actual past experience and are generally estimated as a percentage of sales over the warranty period. Changes in our product warranty liability during the first six months of 2024 and 2023 were as follows:

 

   

Six-month period ended June 30,

 
   

2024

   

2023

 

Accrued warranty obligations – beginning

  $ 547     $ 323  

Accruals for warranties issued

    389       172  

Settlements made

    (147 )     (62 )

Accrued warranty obligations – ending

  $ 789     $ 433  

 

 

Contingencies and Legal Matters

 

We are subject to legal proceedings and claims that arise from time to time in the normal course of business. We believe that the final disposition of any such matters will not have a material adverse effect on the Company’s financial position, results of operations or cash flows. However, recognizing that legal matters are subject to inherent uncertainties, there exists the possibility that ultimate resolution of these matters could have a material adverse impact on the Company’s financial position, results of operations or cash flows. We are not aware of any such situations at this time.

 

 

 

9.

REVENUE RECOGNITION

 

Revenues are generated from the sale of products. Performance obligations are met and revenue is recognized upon transfer of control to the customer, which is generally upon shipment. When contract terms require transfer of control upon delivery at a customer’s location, revenue is recognized on the date of delivery. For products shipped under vendor-managed inventory arrangements, revenue is recognized and billed when the product is consumed by the customer, at which point control has transferred and there are no further obligations by the Company. Revenue is measured as the amount of consideration we expect to receive in exchange for shipped product. Sales, value-added and other taxes billed and collected from customers are excluded from revenue. Customers, including distributors, do not have a general right of return.

 

Separately priced extended warranty contracts are offered on certain Communications Systems products for a duration of up to eight (8) years. Extended warranties are treated as separate performance obligations and recognized to revenue evenly over the term of the respective contract. Revenue not yet recognized on extended warranty contracts is recorded as deferred revenue on the consolidated balance sheet. For the three-month and six-month periods ended June 30, 2024, revenue recognized on extended warranties was $71 and $143, respectively.

 

As of June 30, 2024, there was deferred revenue on extended warranty contracts of $1,264, comprised of $287 expected to be recognized as revenue within one (1) year and classified as accrued expenses and other current liabilities on our consolidated balance sheet, and $977 expected to be recognized as revenue over the remaining duration of the respective contracts and classified as other noncurrent liabilities on our consolidated balance sheet.

 

As of December 31, 2023, there was deferred revenue on extended warranty contracts of $1,407, comprised of $287 expected to be recognized as revenue within one (1) year and classified as accrued expenses and other current liabilities on our consolidated balance sheet, and $1,120 expected to be recognized as revenue evenly over the remaining duration of the respective contracts and classified as other noncurrent liabilities on our consolidated balance sheet.

 

13

 

As of June 30, 2024 and December 31, 2023, the Company had no other unsatisfied performance obligations for contracts with an original expected duration of greater than one year. Pursuant to Topic 606, we have applied the practical expedient with respect to disclosure of the deferral and future expected timing of revenue recognition for transaction price allocated to remaining performance obligations.

 

 

 

10.

BUSINESS SEGMENT INFORMATION

 

We report our results in two operating segments: Battery & Energy Products and Communications Systems. The Battery & Energy Products segment includes Lithium 9-volt, cylindrical and various other non-rechargeable batteries, in addition to rechargeable batteries, uninterruptable power supplies, charging systems and accessories. The Communications Systems segment includes RF amplifiers, power supplies, cable and connector assemblies, amplified speakers, equipment mounts, case equipment, man-portable systems, integrated communication systems for fixed or vehicle applications and communications and electronics systems design. We believe that reporting performance at the gross profit level is the best indicator of segment performance. 

 

Three-month period ended June 30, 2024:

 

   

Battery &

Energy

Products

   

Communications

Systems

   

Corporate

   

Total

 

Revenues

  $ 36,683     $ 6,300     $ -     $ 42,983  

Segment contribution

    9,953       1,610       (7,646 )     3,917  

Other expense

                    (71 )     (71 )

Income tax provision

                    (853 )     (853 )

Non-controlling interest

                    (24 )     (24 )

Net income attributable to Ultralife

                          $ 2,969  

 

Three-month period ended June 30, 2023:

 

   

Battery &

Energy

Products

   

Communications

Systems

   

Corporate

   

Total

 

Revenues

  $ 33,861     $ 8,831     $ -     $ 42,692  

Segment contribution

    7,543       3,045       (6,923 )     3,665  

Other income

                    1,058       1,058  

Income tax provision

                    (1,375 )     (1,375 )

Non-controlling interest

                    (8 )     (8 )

Net income attributable to Ultralife

                          $ 3,340  

 

Six-month period ended June 30, 2024:

 

   

Battery &

Energy

Products

   

Communications

Systems

   

Corporate

   

Total

 

Revenues

  $ 71,672     $ 13,238     $ -     $ 84,910  

Segment contribution

    18,939       4,094       (15,053 )     7,980  

Other expense

                    (527 )     (527 )

Income tax provision

                    (1,556 )     (1,556 )

Non-controlling interest

                    (37 )     (37 )

Net income attributable to Ultralife

                          $ 5,860  

 

14

 

Six-month period ended June 30, 2023:

 

   

Battery &

Energy

Products

   

Communications

Systems

   

Corporate

   

Total

 

Revenues

  $ 62,331     $ 12,277     $ -     $ 74,608  

Segment contribution

    14,055       3,969       (14,333 )     3,691  

Other income

                    564       564  

Income tax provision

                    (1,242 )     (1,242 )

Non-controlling interest

                    (19 )     (19 )

Net income attributable to Ultralife

                          $ 2,994  

 

 

The following tables disaggregate our business segment revenues by major source and geography.

 

Commercial and Government/Defense Revenue Information:

 

Three-month period ended June 30, 2024:

 

   

Total

Revenue

   

Commercial

   

Government/

Defense

 

Battery & Energy Products

  $ 36,683     $ 27,664     $ 9,019  

Communications Systems

    6,300       -       6,300  

Total

  $ 42,983     $ 27,664     $ 15,319  
              64 %     36 %

 

Three-month period ended June 30, 2023:

 

   

Total

Revenue

   

Commercial

   

Government/

Defense

 

Battery & Energy Products

  $ 33,861     $ 26,950     $ 6,911  

Communications Systems

    8,831       -       8,831  

Total

  $ 42,692     $ 26,950     $ 15,742  
              63 %     37 %

 

Six-month period ended June 30, 2024:

 

   

Total

Revenue

   

Commercial

   

Government/

Defense

 

Battery & Energy Products

  $ 71,672     $ 51,804     $ 19,868  

Communications Systems

    13,238       -       13,238  

Total

  $ 84,910     $ 51,804     $ 33,106  
              61 %     39 %

 

Six-month period ended June 30, 2023:

 

   

Total

Revenue

   

Commercial

   

Government/

Defense

 

Battery & Energy Products

  $ 62,331     $ 49,169     $ 13,162  

Communications Systems

    12,277       -       12,277  

Total

  $ 74,608     $ 49,169     $ 25,439  
              66 %     34 %

 

15

 

U.S. and Non-U.S. Revenue Information1:

 

Three-month period ended June 30, 2024:

 

   

Total

Revenue

   

United

States

   

Non-United

States

 

Battery & Energy Products

  $ 36,683     $ 19,412     $ 17,271  

Communications Systems

    6,300       3,987       2,313  

Total

  $ 42,983     $ 23,399     $ 19,584  
              54 %     46 %

 

Three-month period ended June 30, 2023:

 

   

Total

Revenue

   

United

States

   

Non-United

States

 

Battery & Energy Products

  $ 33,861     $ 17,394     $ 16,467  

Communications Systems

    8,831       3,945       4,886  

Total

  $ 42,692     $ 21,339     $ 21,353  
              50 %     50 %

 

Six-month period ended June 30, 2024:

 

   

Total

Revenue

   

United

States

   

Non-United

States

 

Battery & Energy Products

  $ 71,672     $ 39,015     $ 32,657  

Communications Systems

    13,238       8,845       4,393  

Total

  $ 84,910     $ 47,860     $ 37,050  
              56 %     44 %

 

Six-month period ended June 30, 2023:

 

   

Total

Revenue

   

United

States

   

Non-United

States

 

Battery & Energy Products

  $ 62,331     $ 31,162     $ 31,169  

Communications Systems

    12,277       6,822       5,455  

Total

  $ 74,608     $ 37,984     $ 36,624  
              51 %     49 %

 

1 Sales classified to U.S. include shipments to U.S.-based prime contractors which in some cases may serve non-U.S. projects.

 

16

 

 

Item 2. MANAGEMENTS DISCUSSION AND ANALYSIS OF FINANCIAL CONDITION AND RESULTS OF OPERATIONS

 

Forward-Looking Statements

 

The Private Securities Litigation Reform Act of 1995 provides a “safe harbor” for forward-looking statements. This report contains certain forward-looking statements and information that are based on the beliefs of management as well as assumptions made by and information currently available to management. The statements contained in this report relating to matters that are not historical facts are forward-looking statements that involve risks and uncertainties, including, but not limited to, changes in economic conditions including inflation and supply chain disruptions affecting our business, revenues and earnings adversely; our reliance on certain key customers; reductions or delays in U.S. and foreign military spending; our efforts to develop new products or new commercial applications for our products; potential disruptions in our supply of raw materials and components; breaches in information systems security and other disruptions in our information technology systems; our ability to recruit and retain top management and key personnel; our resources being overwhelmed by our growth; the continued impact of COVID-19, or other pandemics that may arise, causing delays in the manufacture and delivery of our mission critical products to end customers; the unique risks associated with our China operations; fluctuations in the price of oil and the resulting impact on the demand for downhole drilling; possible future declines in demand for the products that use our batteries or communications systems; variability in our quarterly and annual results and the price of our common stock; safety risks, including the risk of fire; rising interest rates increasing the cost of our variable borrowings; purchases by our customers of product quantities not meeting the volume expectations in our supply agreements; potential costs attributable to the warranties we supply with our products and services; our inability to comply with changes to the regulations for the shipment of our products; our entrance into new end-markets which could lead to additional financial exposure; negative publicity concerning Lithium-ion batteries; our ability to utilize our net operating loss carryforwards; our exposure to foreign currency fluctuations; possible impairments of our goodwill and other intangible assets; the risk that we are unable to protect our proprietary and intellectual property; rules and procedures regarding contracting with the U.S. and foreign governments; exposure to possible violations of the U.S. Foreign Corrupt Practices Act, the U.K. Bribery Act or other anti-corruption laws; known and unknown environmental matters; possible audits of our contracts by the U.S. and foreign governments and their respective defense agencies; our ability to comply with government regulations regarding the use of “conflict minerals”; and other risks and uncertainties, certain of which are beyond our control. Should one or more of these risks or uncertainties materialize, or should underlying assumptions prove incorrect, actual results may differ materially from those forward-looking statements described herein. When used in this report, the words “anticipate,” “believe,” “estimate,” “expect,” “seek,” “project,” “intend,” “plan,” “may,” “will,” “should,” “foresee,” “could,” “likely,” or words of similar import are intended to identify forward-looking statements. For further discussion of certain of the matters described above and other risks and uncertainties, see Item 1A, “Risk Factors” in our Annual Report on Form 10-K for the year ended December 31, 2023.

 

Although we base these forward-looking statements on assumptions that we believe are reasonable when made, we caution you that forward-looking statements are not guarantees of future performance and that our actual results of operations, financial condition and liquidity and developments in the industries in which we operate may differ materially from those made in or suggested by the forward-looking statements contained herein. In addition, even if our results of operations, financial condition and liquidity and the development of the industries in which we operate are consistent with the forward-looking statements contained in this document, those results or developments may not be indicative of results or developments in subsequent periods. Given these risks and uncertainties, you are cautioned not to place undue reliance on these forward-looking statements. Any forward-looking statements that we make herein speak only as of the date of those statements, and we undertake no obligation to update those statements or to publicly announce the results of any revisions to any of those statements to reflect future events or developments. Comparisons of results for current and any prior periods are not intended to express any future trends or indications of future performance, unless expressed as such, and should only be viewed as historical data.

 

Undue reliance should not be placed on our forward-looking statements. Except as required by law, we disclaim any obligation to update any risk factors or to publicly announce the results of any revisions to any of the forward-looking statements to reflect new information or risks, future events or other developments.

 

The following Management’s Discussion and Analysis of Financial Condition and Results of Operations (“MD&A”) should be read in conjunction with the consolidated financial statements and notes thereto in Part I, Item 1 of this Form 10-Q, and the consolidated financial statements and notes thereto and risk factors in our Annual Report on Form 10-K for the year ended December 31, 2023.

 

17

 

The financial information in this MD&A is presented in thousands of dollars, except for share and per share amounts, unless otherwise specified.

 

 

General

 

We offer products and services ranging from power solutions to communications and electronics systems to customers across the globe in the government, defense and commercial sectors. With an emphasis on strong engineering and a collaborative approach to problem solving, we design and manufacture power and communications systems including rechargeable and non-rechargeable batteries, charging systems, communications and electronics systems and accessories, and custom engineered systems related to those product lines. We continually evaluate ways to grow, including the design, development and sale of new products, expansion of our sales force to penetrate new markets and territories, as well as seeking opportunities to expand through acquisitions.

 

We sell our products worldwide through a variety of trade channels, including original equipment manufacturers (“OEMs”), industrial and defense supply distributors, and directly to U.S. and foreign defense departments. We enjoy strong name recognition in our markets under our Ultralife®, Ultralife HiRate®, Ultralife Thin Cell®, Ultralife Batteries Inc.®, Lithium Power®, McDowell Research®, AMTITM, ABLETM, ACCUTRONICSTM, ACCUPROTM, ENTELLIONTM, SWE Southwest Electronic Energy GroupTM, SWE SEASAFETM, Excell Battery GroupTM and Criterion GaugeTM brands, among others. We have sales, operations and product development facilities in North America, Europe and Asia.

 

We report our results in two operating segments: Battery & Energy Products and Communications Systems. The Battery & Energy Products segment includes Lithium 9-volt, cylindrical, thin cell and other non-rechargeable batteries, in addition to rechargeable batteries, uninterruptable power supplies, charging systems and accessories. The Communications Systems segment includes RF amplifiers, power supplies, cable and connector assemblies, amplified speakers, equipment mounts, case equipment, man-portable systems, integrated communication systems for fixed or vehicle applications and communications and electronics systems design. We believe that reporting performance at the gross profit level is the best indicator of segment performance. As such, we report segment performance at the gross profit level and operating expenses as Corporate charges. (See Note 10 in the notes to consolidated financial statements in Item 1 of Part 1 of this Form 10-Q.)

 

Our website address is www.ultralifecorporation.com. We make available free of charge via a hyperlink on our website (see Investor Relations link on the website) our annual reports on Form 10-K, proxy statements, quarterly reports on Form 10-Q, current reports on Form 8-K, and any amendments to those reports and statements as soon as reasonably practicable after such material is electronically filed with or furnished to the Securities and Exchange Commission (“SEC”). We will provide copies of these reports upon written request to the attention of Philip A. Fain, CFO, Treasurer and Secretary, Ultralife Corporation, 2000 Technology Parkway, Newark, New York, 14513. Our filings with the SEC are also available through the SEC website at www.sec.gov or at the SEC Public Reference Room at 100 F Street, N.E., Washington, D.C. 20549 or by calling 1-800-SEC-0330.

 

 

Overview

 

Consolidated revenues of $42,983 for the three-month period ended June 30, 2024, increased by $291 or 0.7%, over $42,692 for the three-month period ended June 30, 2023. Sales for our Battery & Energy Products segment increased 8.3% from $33,861 in the second quarter of 2023 to $36,683 for the second quarter of 2024, and sales for our Communications Systems segment decreased 28.6% from $8,831 to $6,300.

 

Gross profit was $11,563, or 26.9% of revenue, for the three-month period ended June 30, 2024, compared to $10,588, or 24.8% of revenue, for the same quarter a year ago. The 210-basis point improvement primarily resulted from higher factory volume and efficiencies resulting from our concerted effort to level-load production more evenly across the 2024 quarter, as well as improved price realization for our Battery & Energy Products segment, partially offset by a less favorable product sales mix for our Communications Systems business.

 

Operating expenses increased to $7,646 for the three-month period ended June 30, 2024, compared to $6,923 for the three-month period ended June 30, 2023. The increase of $723 or 10.4% was primarily attributable to investments in new product development, the addition of experienced sales resources and higher executive variable compensation costs accrued in the second quarter of 2024. Operating expenses represented 17.8% of revenues compared to 16.2% of revenues for the year-earlier period.

 

18

 

Operating income for the three-month period ended June 30, 2024 was $3,917, or 9.1% of revenues, compared to $3,665, or 8.6% of revenues, for the year-earlier period. The increase in operating income primarily resulted from the 210-basis point improvement in gross margin.

 

Other income for the second quarter of 2024 includes a preliminary payment of $235 from our insurance carrier pertaining to the ransomware cyberattack experienced by the Company in the first quarter of 2023. Other income for the second quarter of 2023 includes $1,544 attributable to an Employee Retention Credit (“ERC”) of under Section 2301 of the Coronavirus Aid, Relief and Economic Security Act which was filed with the Internal Revenue Service during that period.

 

Net income attributable to Ultralife Corporation was $2,969 or $0.18 per diluted share on a GAAP basis, compared to net income of $3,340 or 0.21 per diluted share for the second quarter of 2023.  Adjusted EPS was $0.22 on a diluted basis for the second quarter of 2024, compared to $0.29 for the 2023 period.  Adjusted EPS excludes the provision for deferred taxes of $744 which primarily represents non-cash charges for U.S. taxes which we expect will be fully offset by net operating loss carryforwards and other tax credits for the foreseeable future.  Recognition of the ERC in the second quarter of 2023 increased GAAP and Adjusted EPS by $0.07 and $0.10, respectively for that period.  See the section “Adjusted EPS” on Page 24 for a reconciliation of adjusted EPS to EPS.

 

Adjusted EBITDA, defined as net income (loss) attributable to Ultralife Corporation before net interest expense, provision (benefit) for income taxes, depreciation and amortization, and stock-based compensation expense, plus/minus expenses/income that we do not consider reflective of our ongoing operations, amounted to $5,415, or 12.6% of revenues, for the second quarter of 2024, compared to $6,296 including $1,544 for the ERC, or 14.7% of revenues, for the second quarter of 2023. See the section “Adjusted EBITDA” beginning on page 22 for a reconciliation of adjusted EBITDA to net income (loss) attributable to Ultralife Corporation.

 

Our main priorities continue to be gross margin increases through focused initiatives on material deflation, lean productivity, and scrap reduction for both businesses, and growing our opportunity funnels and customer wins to continue fueling our growth. We remain optimistic that we are well positioned to sustain profitable growth, generate incremental cash flow to further reduce our debt, and invest in strategic capital expenditures and accretive acquisitions.

 

 

Results of Operations

 

Three-Month Periods Ended June 30, 2024 and June 30, 2023

 

Revenues. Consolidated revenues for the three-month period ended June 30, 2024 were $42,983, an increase of $291, or 0.7%, over $42,692 for the three-month period ended June 30, 2023. Overall, commercial sales increased 2.6% and government/defense sales decreased 2.7%.

 

Battery & Energy Products revenues increased $2,822, or 8.3%, from $33,861 for the three-month period ended June 30, 2023 to $36,683 for the three-month period ended June 30, 2024, the highest revenue quarter for the segment in the Company’s history. The revenue growth was primarily attributable to an increase in government/defense sales of 30.5% reflecting strong demand from our U.S.-based global prime, and an increase in commercial sales of 2.6% reflecting medical market sales growth of 20.1%, partially offset by a 10.9% decline in oil & gas market sales.

 

Communications Systems sales decreased $2,531, or 28.7%, from $8,831 for the three-month period ended June 30, 2023 to $6,300 for the three-month period ended June 30, 2024. The decrease was primarily attributable to shipments in the 2023 period of vehicle-amplifier adaptor orders to a global defense contractor for the U.S. Army and of integrated systems of amplifiers and radio vehicle mounts to a major international defense contractor for an ongoing allied country government/defense modernization program which had been delayed from earlier periods due to supply chain disruptions.

 

 

Cost of Products Sold / Gross Profit. Cost of products sold totaled $31,420 for the quarter ended June 30, 2024, a decrease of $684, or 2.1%, from the $32,104 reported for the three-month period ended June 30, 2023. Consolidated cost of products sold as a percentage of total revenue decreased from 75.2% for the three-month period ended June 30, 2023 to 73.1% for the three-month period ended June 30, 2024. Correspondingly, consolidated gross margin increased from 24.8% for the three-month period ended June 30, 2023, to 26.9% for the three-month period ended June 30, 2024, primarily reflecting higher factory volume and efficiencies resulting from our concerted effort to level-load production more evenly across the 2024 quarter, as well as improved price realization for our Battery & Energy Products segment, partially offset by a less favorable product sales mix for our Communications Systems business.

 

19

 

For our Battery & Energy Products segment, gross profit for the second quarter of 2024 was $9,953, an increase of $2,410 or 32.0% from gross profit of $7,543 for the second quarter of 2024. Battery & Energy Products’ gross margin of 27.1% increased by 480-basis points from the 22.3% gross margin for the year-earlier period, primarily due to higher cost absorption and more efficiencies resulting from a concerted effort to level-load production more evenly across the 2024 quarter, as well as improved price realization. The 2023 period was impacted by lingering inefficiencies resulting from the January 2023 cyberattack, disposition of certain non-conforming materials and higher material and logistics costs.

 

For our Communications Systems segment, gross profit for the second quarter of 2024 was $1,610 or 25.6% of revenues, compared to gross profit of $3,045 or 34.5% of revenues for the second quarter of 2023. The decrease in gross margin was primarily due to a more favorable product sales mix in the year-earlier period.

 

Operating Expenses. Operating expenses for the three-month period ended June 30, 2024 were $7,646, an increase of $723, or 10.4%, from the $6,923 for the three-month period ended June 30, 2023. The increase was primarily attributable to investments in new product development, the addition of experienced sales resources and higher executive variable compensation costs accrued in the second quarter of 2024.

 

Overall, operating expenses were 17.8% of revenue for the quarter ended June 30, 2024 compared to 16.2% of revenue for the quarter ended June 30, 2023.  Amortization expense associated with intangible assets related to our acquisitions was $227 for the second quarter of 2024 ($202 in selling, general and administrative expenses and $25 in research and development costs), identical to the $227 for the second quarter of 2023 ($203 in selling, general, and administrative expenses and $24 in research and development costs). Research and development costs were $1,997 for the three-month period ended June 30, 2024, an increase of $219 or 12.3%, from $1,778 for the three-month period ended June 30, 2023. The increase is largely attributable to the timing of new product development in both of our businesses as we aggressively pursue both government/defense major programs and commercial opportunities. Selling, general, and administrative expenses were $5,649 for the three-month period ended June 30, 2024, an increase of $504 or 9.8% from $5,145 for the second quarter of 2023. The period over period increase was primarily attributable to higher executive variable compensation costs accrued in the second quarter of 2024 as well as the addition of experienced sales resources. 

 

Other (Expense) Income. Other (expense) income totaled $(71) for the three-month period ended June 30, 2024 compared to $1,058 for the three-month period ended June 30, 2023.  Other income for the second quarter of 2024 includes a preliminary payment of $235 from our insurance carrier pertaining to the ransomware cyberattack experienced by the Company in the first quarter of 2023.  Other income for the second quarter of 2023 includes $1,544 attributable to an Employee Retention Credit (“ERC”) claimed by the Company under Section 2301 of the Coronavirus Aid, Relief and Economic Security Act.  Interest and financing expense decreased $22, or 5.1%, from ($440) for the second quarter of 2023 to ($418) for the comparable period in 2024. The decrease is due to the paydown of debt in the second quarter of 2024. Excluding the $235 gain on insurance proceeds, miscellaneous income was $112 for the second quarter of 2024 and excluding the $1,544 gain for the ERC, miscellaneous income (expense) amounted to ($46) for the second quarter of 2023, primarily attributable to foreign exchange gains and loss due to fluctuations in foreign currency exchange rates.

 

Income Taxes. For the three-month period ended June 30, 2024, Ultralife recognized an income tax provision of $853, comprised of a current provision of $109 expected to be paid on income primarily in foreign jurisdictions and a deferred tax provision of $744 which primarily represents non-cash charges for U.S. taxes which we expect will be fully offset by net operating loss carryforwards and other tax credits for the foreseeable future. This compares to a tax provision of $1,375 comprised of a current provision of $97 and deferred expense of $1,278 for the three-month period ended June 30, 2023.  Our effective tax rate was 22.2% for the second quarter of 2024 as compared to 29.1% for the second quarter of 2023, primarily attributable to the geographic mix of our operating results and the larger impact of discrete adjustments for employee stock option exercises in the current year. See Note 6 to the consolidated financial statements in Item 1 of Part I of this Form 10-Q for additional information regarding our income taxes.

 

Net Income Attributable to Ultralife. Net income attributable to Ultralife was $2,969 or $0.18 per share – basic and diluted on a GAAP basis for the three-month period ended June 30, 2024 compared to $3,340, or $0.21 per share – basic and diluted for the three-month period ended June 30, 2023.  Adjusted EPS was $0.22 on a diluted basis for the second quarter of 2024, compared to $0.29 for the second quarter of 2023.  Adjusted EPS excludes the provision for deferred taxes of $744 and $1,278 for the 2024 and 2023 periods, respectively, which primarily represent non-cash charges for U.S. taxes which we expect will be fully offset by net operating loss carryforwards and other tax credits for the foreseeable future.  Recognition of the ERC in the second quarter of 2023 increased GAAP and Adjusted EPS by $0.07 and $0.10, respectively for that period.  See the section “Adjusted EPS” on Page 24 for a reconciliation of adjusted EPS to EPS. 

 

20

 

Weighted average shares outstanding used to compute diluted earnings per share decreased from 16,143,686 for the second quarter of 2023 to 16,825,321 for the second quarter of 2024. The increase is attributable to stock option exercises since the second quarter of 2023 and an increase in the average stock price used to compute diluted shares from $4.52 for the second quarter of 2023 to $10.65 for the second quarter of 2024. Accordingly, dilutive shares of 2,334 were added to basic weighted average shares for the 2023 period compared to 257,068 for the 2024 period.

 

 

Six-Month Periods Ended June 30, 2024 and June 30, 2023

 

Revenues. Consolidated revenues for the six-month period ended June 30, 2024 were $84,910, an increase of $10,302, or 13.8%, over $74,608 for the six-month period ended June 30, 2023. Overall, government/defense sales increased $7,667 or 30.1% and commercial sales increased $2,635 or 5.4%. On January 25, 2023, the Company experienced a ransomware cyberattack which impacted our ability to process orders, ship products, provide services to our customers and effectively manage our sales and operating planning process over a several week period for our Newark, NY location and an even longer period for our Virginia Beach, VA location. A large portion of our time during the quarter was devoted to data restoration, systems security augmentation, and regulatory reporting of the cyberattack, all of which were successfully accomplished with no ransom paid. Management continues to work on its cybersecurity insurance claim covering the cost of engaging external cybersecurity experts and the business interruption impact.

 

Battery & Energy Products revenues increased $9,341, or 15.0%, from $62,331 for the six-month period ended June 30, 2023 to $71,672 for the six-month period ended June 30, 2024. The increase was attributable to a $6,706 or 50.9% increase in government/defense sales and a $2,635 or 5.4% increase in commercial sales. The increase in government/defense sales primarily reflects continued strong demand from our largest U.S.-based global prime. The growth in commercial sales was driven by a $5,266 or 33.3% increase in medical sales due to continuing surging demand for our core medical battery products from global medical device OEM’s and a $96 or 0.8% increase in industrial sales, partially offset by a decrease of $2,727 or 12.4% in oil & gas sales due primarily to general economic conditions.

 

Communications Systems revenues increased $961 or 7.8%, from $12,277 for the six-month period ended June 30, 2023 to $13,238 for the six-month period ended June 30, 2024. This increase was primarily attributable to shipments of EL8000 server cases to a large multinational information technology company, integrated systems of amplifiers and radio vehicle mounts to a major international defense contractor under an ongoing allied country government/defense modernization program, and power systems to a U.S.-based global prime.

 

Operating Expenses. Operating expenses for the six-month period ended June 30, 2024 were $15,053, an increase of $720 or 5.0% from the $14,333 for the six-month period ended June 30, 2023. The increase is primarily attributable to commissions on higher sales, greater participation in trade shows and higher executive variable compensation costs accrued in the first half of 2024. Both periods reflected continued tight control over discretionary spending.

 

Overall, operating expenses as a percentage of revenues were 17.7% for the six-month period ended June 30, 2024 compared to 19.2% for the six-month period ended June 30, 2023.  Amortization expense associated with intangible assets related to our acquisitions was $455 for the first six months of 2023 ($405 in selling, general and administrative expenses and $50 in research and development costs), compared with $436 for the first six months of 2023 ($388 in selling, general, and administrative expenses and $48 in research and development costs). Research and development costs were $3,753 for the six-month period ended June 30, 2024, a decrease of $57 or 1.5%, from $3,810 for the six-months ended June 30, 2023. Selling, general, and administrative expenses increased $777, or 7.4%, from $10,523 for the first six months of 2023 to $11,300 for the first six months of 2024.  The increase primarily resulted from commissions on higher sales, greater participation in trade shows and higher executive variable compensation costs accrued in the first half of 2024.

 

Other (Expense) Income. Other (expense) income totaled ($527) for the six-month period ended June 30, 2024 compared to $564 for the six-month period ended June 30, 2023. Other income (expense) for the 2024 period includes a preliminary payment of $235 from our insurance carrier pertaining to the cyberattack experienced by the Company in the first quarter of 2023, and other income for the 2023 period includes $1,544 attributable to an ERC claimed by the Company under Section 2301 of the Coronavirus Aid, Relief and Economic Security Act. Interest and financing expense increased $74, or 8.6%, from ($864) for the first six months of 2023 to ($938) for the comparable period in 2024. The increase is primarily due to rising interest rates which was partially offset by reductions of debt primarily during May and June of 2024. Excluding the $235 gain on insurance proceeds in 2024, miscellaneous income (expense) was $176, and excluding the $1,544 ERC gain in the 2023 period, miscellaneous income (expense) amounted to ($116), primarily attributable to foreign exchange gains and loss due to fluctuations in foreign currency exchange rates.

 

21

 

Income Taxes. The income tax provision for the 2024 six-month period was $1,556 compared to $1,242 for the 2023 six-month period. Our effective tax rate decreased to 20.9% from 29.2% for the 2023 period, primarily due to the geographic mix of our operating results and the larger impact of discrete adjustments for employee stock option exercises in the current period. The income tax provision for the first six months of 2024 is comprised of a $162 current provision for taxes expected to be paid on income primarily in foreign jurisdictions, representing a cash-based effective tax rate of 2.0%, and a $1,394 deferred tax provision which primarily represents non-cash charges for U.S. taxes which we expect will be fully offset by net operating loss carryforwards and other tax credits for the foreseeable future.  For the comparable 2023 period, the income tax provision was comprised of a $354 current provision for taxes expected to be paid on income primarily in foreign jurisdictions, representing a cash-based effective tax rate of 8.3%, and an $888 deferred tax provision which primarily represents non-cash charges for U.S. taxes that we expect will be fully offset by net operating loss carryforwards and other tax credits for the foreseeable future.  The period over period change in the cash-based effective tax rate is primarily attributable to the geographic mix of our operating results. See Note 6 to the consolidated financial statements in Item 1 of Part I of this Form 10-Q for additional information regarding our income taxes.

 

Net Income Attributable to Ultralife. Net income attributable to Ultralife was $5,860, or $0.36 per share – basic $0.35 per share - diluted on a GAAP basis for the six-month period ended June 30, 2024, compared to $2,994, or $0.19 per share – basic and diluted, for the six-month period ended June 30, 2023. Adjusted EPS was $0.44 on a diluted basis for the 2024 period, compared to $0.24, for the 2023 period. Adjusted EPS excludes the provision for deferred taxes of $1,394 and $888 for the 2024 and 2023 periods, respectively, which primarily represents non-cash charges for U.S. taxes which we expect will be fully offset by net operating loss carryforwards and other tax credits for the foreseeable future.  See the section “Adjusted EPS” on Page 24 for a reconciliation of adjusted EPS to EPS. 

 

Weighted average shares outstanding used to compute diluted earnings per share increased from 16,140,528 for the first six-months of 2023 to 16,661,175 for the first six-months of 2024. The increase is attributable to stock option exercises since the second quarter of 2023 and an increase in the average stock price used to compute diluted shares from $4.25 for the six-month period ended June 30, 2023 to $9.41 for the six-month period ended June 30, 2024. Accordingly diluted shares of 179,112 were added to basic weighted average shares in 2024 compared to 2,157 in 2023.

 

 

Adjusted EBITDA

 

In evaluating our business, we consider and use adjusted EBITDA, a non-GAAP financial measure, as a supplemental measure of our operating performance. We define adjusted EBITDA as net income (loss) attributable to Ultralife before interest expense, provision (benefit) for income taxes, depreciation and amortization, and stock-based compensation expense, plus/minus expense/income that we do not consider reflective of our ongoing continuing operations. We also use adjusted EBITDA as a supplemental measure to review and assess our operating performance and to enhance comparability between periods. We believe the use of adjusted EBITDA facilitates investors’ understanding of operating performance from period to period by backing out potential differences caused by variations in such items as capital structures (affecting relative interest expense and stock-based compensation expense), the amortization of intangible assets acquired through our business acquisitions (affecting relative amortization expense and provision (benefit) for income taxes), the age and book value of facilities and equipment (affecting relative depreciation expense) and one-time charges/benefits relating to income taxes. We also present adjusted EBITDA from operations because we believe it is frequently used by securities analysts, investors and other interested parties as a measure of financial performance. We reconcile adjusted EBITDA to net income (loss) attributable to Ultralife, the most comparable financial measure under GAAP.

 

22

 

We use adjusted EBITDA in our decision-making processes relating to the operation of our business together with GAAP financial measures such as operating income (loss). We believe that adjusted EBITDA permits a comparative assessment of our operating performance, relative to our performance based on our GAAP results, while eliminating the effects of depreciation and amortization, which may vary from period to period without any correlation to underlying operating performance, and of stock-based compensation, which is a non-cash expense that varies widely among companies. We believe that by presenting adjusted EBITDA, we assist investors in gaining a better understanding of our business on a going forward basis. We provide information relating to our adjusted EBITDA so that securities analysts, investors and other interested parties have the same data that we employ in assessing our overall operations. We believe that trends in our adjusted EBITDA are a valuable indicator of our operating performance on a consolidated basis and of our ability to produce operating cash flows to fund working capital needs, to service debt obligations and to fund capital expenditures.

 

The term adjusted EBITDA is not defined under GAAP and is not a measure of operating income (loss), operating performance or liquidity presented in accordance with GAAP. Our adjusted EBITDA has limitations as an analytical tool, and when assessing our operating performance, adjusted EBITDA should not be considered in isolation or as a substitute for net income (loss) attributable to Ultralife or other consolidated statement of operations data prepared in accordance with GAAP. Some of these limitations include, but are not limited to, the following:

 

 

Adjusted EBITDA does not reflect (1) our cash expenditures or future requirements for capital expenditures or contractual commitments; (2) changes in, or cash requirements for, our working capital needs; (3) the interest expense, or the cash requirements necessary to service interest or principal payments, on our debt; (4) income taxes or the cash requirements for any tax payments; and (5) all of the costs associated with operating our business;

 

 

Although depreciation and amortization are non-cash charges, the assets being depreciated and amortized often will have to be replaced in the future, and adjusted EBITDA from continuing operations does not reflect any cash requirements for such replacements;

 

 

While stock-based compensation is a component of cost of products sold and operating expenses, the impact on our consolidated financial statements compared to other companies can vary significantly due to such factors as assumed life of the stock-based awards and assumed volatility of our common stock; and

 

 

Other companies may calculate adjusted EBITDA differently than we do, limiting its usefulness as a comparative measure.

 

We compensate for these limitations by relying primarily on our GAAP results and using adjusted EBITDA only on a supplemental basis. Neither current nor potential investors in our securities should rely on adjusted EBITDA as a substitute for any GAAP measures and we encourage investors to review the following reconciliation of adjusted EBITDA to net income attributable to Ultralife Corporation.

 

Adjusted EBITDA is calculated as follows for the periods presented:

 

 

   

Three-Month Period Ended

   

Six-Month Period Ended

 
   

June 30,

   

June 30,

   

June 30,

   

June 30,

 
   

2024

   

2023

   

2024

   

2023

 
                                 

Net income attributable to Ultralife Corporation

  $ 2,969     $ 3,340     $ 5,860     $ 2,994  

Add:

                               

Interest expense

    418       440       938       864  

Income tax provision

    853       1,375       1,556       1,242  

Depreciation expense

    789       760       1,529       1,522  

Amortization expense

    227       227       455       436  

Stock-based compensation expense

    159       154       320       293  

Cybersecurity insurance policy deductible

    -       -       -       100  

Adjusted EBITDA

  $ 5,415     $ 6,296     $ 10,658     $ 7,451  

 

23

 

Adjusted Earnings Per Share

 

In evaluating our business, we consider and use adjusted EPS, a non-GAAP financial measure, as a supplemental measure of our business performance. We define adjusted EPS as net income attributable to Ultralife Corporation excluding the provision (benefit) for deferred income taxes divided by our weighted average shares outstanding on both a basic and diluted basis. We believe that this information is useful in providing period-to-period comparisons of our results by reflecting the portion of our tax provision that will be predominantly offset by our U.S. net operating loss carryforwards and other tax credits for the foreseeable future. We reconcile adjusted EPS to EPS, the most comparable financial measure under GAAP. Neither current nor potential investors in our securities should rely on adjusted EPS as a substitute for any GAAP measures and we encourage investors to review the following reconciliation of adjusted EPS to EPS and net income attributable to Ultralife Corporation.

 

Adjusted EPS is calculated as follows for the periods presented:

 

   

Three-Month Period Ended

 
   

June 30, 2024

   

June 30, 2023

 
   

Amount

   

Per

Basic

Share

   

Per

Diluted

Share

   

Amount

   

Per

Basic

Share

   

Per

Diluted

Share

 

Net income attributable to Ultralife Corporation

  $ 2,969     $ .18     $ .18     $ 3,340     $ .21     $ .21  

Deferred tax provision

    744       .04       .04       1,278       .08       .08  

Adjusted net income

  $ 3,713     $ .22     $ .22     $ 4,618     $ .29     $ .29  
                                                 

Weighted Average Shares Outstanding

            16,568       16,825               16,141       16,144  

 

   

Six-Month Period Ended

 
   

June 30, 2024

   

June 30, 2023

 
   

Amount

   

Per

Basic

Share

   

Per

Diluted

Share

   

Amount

   

Per

Basic

Share

   

Per

Diluted

Share

 

Net income attributable to Ultralife Corporation

  $ 5,860     $ .36     $ .35     $ 2,994     $ .19     $ .19  

Deferred tax provision

    1,394       .08       .09       888       .05       .05  

Adjusted net income

  $ 7,254     $ .44     $ .44     $ 3,882     $ .24     $ .24  
                                                 

Weighted Average Shares Outstanding

            16,482       16,661               16,138       16,141  

 

24

 

Liquidity and Capital Resources

 

As of June 30, 2024, cash totaled $6,690, as compared to $10,278 at December 31, 2023. The decrease reflects a $13,679 reduction in our outstanding debt, largely offset by strong income and cash generation during the period.

 

For the six-month period ended June 30, 2024, cash generated from operations was $8,844, as compared to $386 generated for the six-month period ended June 30, 2023. For the 2024 period, cash generated from operations was comprised of net income of $5,897 plus non-cash items totaling $3,730 for depreciation, amortization, stock-based compensation, and deferred taxes, partially offset by $783 attributable to working capital.

 

Cash used in investing activities for the six months ended June 30, 2023 was $732 for capital expenditures, primarily reflecting investments in equipment for new products transitioning to higher-volume manufacturing.

 

Cash used in financing activities for the six months ended June 30, 2024 was $11,743, representing a $13,679 reduction in our outstanding debt, partially offset by $1,936 in cash generated from employee stock option exercise proceeds during the period.

 

We continue to have significant U.S. net operating loss carryforwards available to utilize as an offset to future taxable income. See Note 6 to the consolidated financial statements of this Form 10-Q for additional information.

 

Going forward, we expect positive operating cash flow and the availability under our Revolving Credit Facility will be sufficient to meet our general funding requirements for the foreseeable future.

 

To provide flexibility in accessing the capital markets, on March 30, 2021, the Company filed a shelf registration statement on Form S-3 (File No. 333-254846) (the “Prior Registration Statement”) registering securities in an aggregate amount of $100,000,000. None of the $100,000,000 of registered securities were sold under the Prior Registration Statement (the “Unsold Securities”). Under the rules of the Securities and Exchange Commission (the “SEC”) the Prior Registration Statement was set to expire on April 2, 2024. Therefore, on March 29, 2024, the Company filed a new shelf registration statement on Form S-3 (File No. 333-278360) (the “New Registration Statement”) to replace the Prior Registration Statement. The New Registration Statement includes all $100,000,000 of the Unsold Securities registered on the Prior Registration Statement. During the grace period afforded by Rule 415(a)(5) under the Securities Act of 1933, as amended (the “Securities Act”), we may offer and sell the Unsold Securities under the Prior Registration Statement until the SEC declares the New Registration Statement effective. Pursuant to Rule 415(a)(6) under the Securities Act, the offering of the Unsold Securities under the Prior Registration Statement will be deemed terminated as of the date of effectiveness of the New Registration Statement. Upon the filing of an appropriate prospectus supplement or supplements under either the Prior Registration Statement, or upon its effectiveness the New Registration Statement, we may offer and sell our securities from time to time in one or more offerings, at our discretion. We intend to use the net proceeds resulting from any sales of these securities for general corporate purposes which may include, but are not limited to, potential acquisitions of complementary businesses or technologies, strategic capital expenditures to expand and protect our competitive position, and investments in the development of transformational, competitively differentiated products for attractive growth markets.

 

 

Commitments

 

As of June 30, 2024, the Company had $6,902 outstanding borrowings on the Revolving Credit Facility and $5,167 on the Term Loan Facility. The Company was in full compliance with all covenants under the Credit Facilities as of June 30, 2024.

 

As of June 30, 2024, we had made commitments to purchase approximately $779 of production machinery and equipment.

 

25

 

Critical Accounting Policies

 

Management exercises judgment in making important decisions pertaining to choosing and applying accounting policies and methodologies in many areas. Not only are these decisions necessary to comply with GAAP, but they also reflect management’s view of the most appropriate manner in which to record and report our overall financial performance. All accounting policies are important, and all policies described in Note 1 to the consolidated financial statements in our 2023 Annual Report on Form 10-K should be reviewed for a greater understanding of how our financial performance is recorded and reported.

 

During the first six months of 2024, there were no significant changes in the manner in which our significant accounting policies were applied or in which related assumptions and estimates were developed.

 

 

Item 4. CONTROLS AND PROCEDURES

 

Evaluation of Disclosure Controls and Procedures

 

Our President and Chief Executive Officer (Principal Executive Officer) and our Chief Financial Officer and Treasurer (Principal Financial Officer) have evaluated our disclosure controls and procedures (as defined in Securities Exchange Act Rules 13a-15(e)) as of the end of the period covered by this quarterly report. Based on this evaluation, our President and Chief Executive Officer and Chief Financial Officer and Treasurer concluded that our disclosure controls and procedures were effective as of such date.

 

Changes in Internal Control Over Financial Reporting

 

There has been no change in our internal control over financial reporting (as defined in Securities Exchange Act Rule 13a-15(f)) that occurred during the fiscal quarter covered by this quarterly report that has materially affected, or is reasonably likely to materially affect, our internal control over financial reporting.

 

26

 

PART II.         OTHER INFORMATION

 

Item 6.         Exhibits

 

Exhibit

Index

 

Exhibit Description

 

Incorporated by Reference from

10.1

 

Fourth Amendment Agreement, dated June 30, 2024, by and among Ultralife Corporation, Southwest Electronic Energy Corporation, CLB, Inc., Ultralife Excell Holding Corp., Ultralife Canada Holding Corp., Excell Battery Corporation USA, Excell Battery Canada ULC and KeyBank National Association

 

Filed herewith

31.1

 

Rule 13a-14(a) / 15d-14(a) CEO Certifications

 

Filed herewith

31.2

 

Rule 13a-14(a) / 15d-14(a) CFO Certifications

 

Filed herewith

32

 

Section 1350 Certifications

 

Furnished herewith

101.INS

 

Inline XBRL Instance Document

 

Filed herewith

101.SCH

 

Inline XBRL Taxonomy Extension Schema Document

 

Filed herewith

101.CAL

 

Inline XBRL Taxonomy Extension Calculation Linkbase Document

 

Filed herewith

101.LAB

 

Inline XBRL Taxonomy Extension Label Linkbase Document

 

Filed herewith

101.PRE

 

Inline XBRL Taxonomy Extension Presentation Linkbase Document

 

Filed herewith

101.DEF

 

Inline XBRL Taxonomy Extension Definition Linkbase Document

 

Filed herewith

104

 

Cover Page Interactive Data File (formatted as Inline XBRL and contained in Exhibit 101)

 

Filed herewith

         
Attached as Exhibit 101 to this report are the following formatted in iXBRL (Inline eXtensible Business Reporting Language): (i) Consolidated Balance Sheets as of June 30, 2024 and December 31, 2023, (ii) Consolidated Statements of Income and Comprehensive Income for the three and six months ended June 30, 2024 and 2023, (iii) Consolidated Statements of Cash Flows for the six months ended June 30, 2024 and 2023, (iv) Consolidated Statements of Changes in Stockholders’ Equity for the three and six months ended June 30, 2024 and 2023, and (v) Notes to Consolidated Financial Statements.

 

27

 

SIGNATURES

 

 

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned thereunto duly authorized.

 

       

ULTRALIFE CORPORATION

 
       

(Registrant)

 
           
 

Date: July 25, 2024

By: /s/

Michael E. Manna

 
       

Michael E. Manna

 
       

President and Chief Executive Officer

 
       

(Principal Executive Officer)

 
           
 

Date: July 25, 2024

By: /s/

Philip A. Fain

 
       

Philip A. Fain

 
       

Chief Financial Officer and Treasurer

 
       

(Principal Financial Officer and

 
       

Principal Accounting Officer)

 

 

28

Exhibit 10.1

 

FOURTH AMENDMENT AGREEMENT

 

This Fourth Amendment Agreement (this “Agreement”) is made and entered into as of this [___] day of June, 2024, by and among ULTRALIFE CORPORATION, a Delaware corporation (“Ultralife”), SOUTHWEST ELECTRONIC ENERGY CORPORATION, a Texas corporation (“Southwest”), CLB, INC., a Texas corporation (“CLB”), ULTRALIFE EXCELL HOLDING CORP., a Delaware corporation (“UEHC”), ULTRALIFE CANADA HOLDING CORP., a Delaware corporation (“UCHC”), EXCELL BATTERY CORPORATION USA, a Texas corporation (“Excell USA”, and together with Ultralife, Southwest, CLB, UEHC and UCHC, collectively, the “Borrowers”, and each individually a “Borrower”), EXCELL BATTERY CANADA ULC, a British Columbia unlimited liability company (“Excell Canada”), the lending institutions currently a party to the Credit Agreement (as hereinafter defined) (each, a “Lender” and collectively, the “Lenders”), and KEYBANK NATIONAL ASSOCIATION (“KeyBank”, and in its capacity as agent for the Lenders under the Credit Agreement, “Agent”).

 

WHEREAS, Lenders, Agent and Borrowers are parties to a certain Credit and Security Agreement dated as of May 31, 2017 (as amended by that certain First Amendment Agreement dated as of May 1, 2019, that certain Second Amendment Agreement dated as of December 13, 2021, and that certain Third Amendment Agreement dated as of November 28, 2022, and as it may from time to time be further amended, restated or otherwise modified or supplemented from time to time, the “Credit Agreement”).

 

WHEREAS, Lenders, Agent and Borrowers desire to amend the Credit Agreement by modifying certain provisions thereof.

 

WHEREAS, unless defined herein, each term used herein shall be defined in accordance with the Credit Agreement.

 

NOW, THEREFORE, in consideration of the premises and of the mutual covenants herein and for other valuable consideration Lenders, Agent, and Credit Parties agree as follows:

 

1.            Article I of the Credit Agreement is hereby amended to delete the definitions of “Applicable Margin”, “Commitment Period” and “Derived Adjusted Daily Simple SOFR Rate” therefrom in their entirety and to insert in place thereof the following:

 

“Applicable Margin” shall mean:

 

(a)         for the period from the Fourth Amendment Closing Date until the Pricing Change Date (as hereinafter defined) related to the fiscal quarter ending June 30, 2024, (i) 210 basis points for Revolving Loans which are SOFR Loans, (ii) 185 basis points for Term Loans B which are SOFR Loans, and (iii) 20 basis points for the Unused Fee; and

 

 

 

(b)         commencing on the Pricing Change Date related to the fiscal quarter ending June 30, 2024, the number of basis points (depending upon whether Loans are Revolving Loans which are SOFR Loans, Term Loans B which are SOFR Loans, or the Unused Fee) set forth in the following matrix, based upon the result of the computation of the Consolidated Senior Leverage Ratio as set forth in the Compliance Certificate for such fiscal period, shall be used to establish the number of basis points that will go into effect on such Pricing Change Date and thereafter, as set forth in each successive Compliance Certificate, as provided below:

 

Consolidated Senior

Leverage Ratio

 

Applicable Basis

Points for Revolving

Loans which are

SOFR Loans

   

Applicable Basis

Points for Term

Loans B which are

SOFR Loans

   

Applicable Basis

Points for

Unused Fee

 

Less than 1.50 to 1.00

    210       185       20  

Greater than or equal to 1.50 to 1.00 but less than 2.50 to 1.00

    225       200       25  

Greater than or equal to 2.50 to 1.00

    240       215       30  

 

Changes to the Applicable Margin (including the first change) shall be effective on the first Business Day of each month following the date upon which the Agent should have received, pursuant to Section 5.3(d) hereof, the Compliance Certificate for the most recently ended fiscal quarter (each a “Pricing Change Date”). The above matrix does not modify or waive, in any respect, the requirements of Section 5.7 hereof, the rights of the Agent and the Lenders to charge the Default Rate, or the rights and remedies of the Agent and the Lenders pursuant to Articles VIII and IX hereof. Notwithstanding anything herein to the contrary, (i) during any period when Borrowers shall have failed to timely deliver the Consolidated financial statements pursuant to Section 5.3(b) hereof or the Compliance Certificate related thereto pursuant to Section 5.3(d) hereof, until such time as the appropriate Consolidated financial statements and Compliance Certificate are delivered, the Applicable Margin shall be the highest rate per annum indicated in the above pricing grid, regardless of the Consolidated Senior Leverage Ratio at such time, and (ii) in the event that any financial information or certification provided to the Agent in the Compliance Certificate is shown to be inaccurate (regardless of whether this Agreement or the Commitment is in effect when such inaccuracy is discovered), and such inaccuracy, if corrected, would have led to the application of a higher Applicable Margin for any period (an “Applicable Margin Period”) than the Applicable Margin applied for such Applicable Margin Period, then (A) the Borrowers shall immediately deliver to the Agent a corrected Compliance Certificate for such Applicable Margin Period, (B) the Applicable Margin shall be determined based on such corrected Compliance Certificate to the extent such change would have resulted in a higher rate during such period, and (C) the Borrowers shall immediately pay to the Agent the accrued additional interest owing as a result of such increased Applicable Margin for such Applicable Margin Period.

 

“Commitment Period” shall mean the period from the Closing Date until May 30, 2028, or such earlier date on which the Commitment shall have been terminated pursuant to Article IX hereof.

 

2

 

“Derived Adjusted Daily Simple SOFR Rate” shall mean a rate per annum equal to the sum of the Applicable Margin (from time to time in effect) for Revolving Loans which are SOFR Loans or Term Loans B which are SOFR loans (as the case may be) plus the Adjusted Daily Simple SOFR rate.

 

2.           Article I of the Credit Agreement is hereby amended to insert the following new definition thereto in the appropriate alphabetical order:

 

“Fourth Amendment Closing Date” shall mean June [___], 2024.

 

3.           Section 2.1A2(iii) of the Credit Agreement is hereby amended to delete each reference to “Applicable Margin for SOFR Loans” contained therein and insert in place thereof “Applicable Margin for Revolving Loans which are SOFR Loans”.

 

4.           As a condition precedent to the effectiveness of this Agreement:

 

(a)    Borrowers shall have delivered to Agent a disbursement direction letter (the “Disbursement Direction Letter”), in form and substance satisfactory to Agent;

 

(b)    Agent shall have received a good standing certificate (or equivalent) available in the jurisdiction of incorporation, formation or organization for each Credit Party from the appropriate governmental officer in such jurisdiction dated not more than 15 days prior to the date hereof;

 

(c)    Agent shall have received for each Credit Party (i) the results of lien searches in such jurisdictions reasonably satisfactory to Agent; and (ii) termination statements and payoff letters reflecting termination of all financing statements and Liens (other than Permitted Liens) previously filed by any party having a security interest in any part of the Collateral or any other property securing the Secured Debt;

 

(d)    Agent shall have received in form and substance satisfactory to Agent, one or more insurance certificates and copies of Credit Parties’ casualty insurance policies, together with loss payable endorsements reasonably satisfactory to Agent naming Agent as Lender loss payee, and copies of Credit Parties’ liability insurance policies, together with endorsements naming Agent as a co-insured;

 

(e)    Borrowers shall have paid to Agent for the pro rata benefit of the Lenders a revolver renewal fee in the amount of $45,000; and

 

(f)    Borrowers shall have paid all reasonable and documented out of pocket legal fees and expenses of Agent incurred in connection with this Agreement.

 

3

 

5.         Each Credit Party hereby represents and warrants to Agent and the Lenders that as of the date hereof: (a) such Credit Party has the legal power and authority to execute and deliver this Agreement, the Disbursement Direction Letter, and each other document, agreement, writing or instrument executed in connection with this Agreement (collectively, the “Amendment Documents”) executed by such Credit Party in connection with this Agreement; (b) the officers (or other authorized Persons) of such Credit Party executing the Amendment Documents have been duly authorized to execute and deliver the same and bind such Credit Party with respect to the provisions thereof; (c) the execution and delivery by such Credit Party of the Amendment Documents to which it is a party and the performance and observance by such Loan Party of the provisions thereof do not violate or conflict with the Organizational Documents of such Credit Party or any law applicable to such Credit Party or result in a breach of any provision of or constitute a default under any other material agreement, instrument or document binding upon or enforceable against such Loan Party; (d) after giving effect to this Agreement, no Default or Event of Default exists under the Loan Documents, nor will any occur upon giving effect to the execution and delivery of the Amendment Documents or by the performance or observance of any provision thereof; (e) such Credit Party does not have any claim or offset against, or defense or counterclaim to, any of such Credit Party’s obligations or liabilities under the Credit Agreement or the other Loan Documents; (f) the representations and warranties set forth in Article VII of the Credit Agreement are true and correct in all material respects (without duplication of materiality qualifiers) on and as of the date hereof, except to the extent such representation or warranty relates to an earlier specified date, in which case such representation and warranty is reaffirmed true and correct in all material respects as of such date; and (g) the Amendment Documents to which such Credit Party is a party constitute a valid and binding obligation of such Credit Party in every respect, enforceable in accordance with their respective terms, except as such enforceability may be limited by any Debtor Relief Laws.

 

6.           In consideration of this Agreement, each Credit Party hereby waives and releases Agent and the Lenders and their respective affiliates, officers, directors, equity holders, agents, attorneys, employees and representatives from any and all such claims, offsets, defenses and counterclaims of which such Credit Party is aware or unaware in connection with the Credit Agreement to the extent arising on or prior to the date hereof, such waiver and release being with full knowledge and understanding of the circumstances and effect thereof and after having consulted legal counsel with respect thereto.

 

7.           Each reference that is made in the Credit Agreement or any other writing shall hereafter be construed as a reference to the Credit Agreement as amended hereby. Except as herein otherwise specifically provided, all provisions of the Credit Agreement shall remain in full force and effect and be unaffected hereby. Each Amendment Document is a Loan Document as defined in the Credit Agreement.

 

8.          Each Credit Party hereby reaffirms its obligations, as applicable, under the Credit Agreement and all other Loan Documents to which such Credit Party is a party, as any of them may from time to time be amended, restated or otherwise modified (the “Reaffirmed Documents”). Each Credit Party agrees (i) that each Reaffirmed Document shall remain in full force and effect following the execution and delivery of this Agreement and any other Amendment Document, and (ii) that all references in any of the Reaffirmed Documents to the “Credit Agreement” or “Loan Agreement” shall be deemed to refer to the Credit Agreement, as amended by this Agreement or as it may be further amended, restated or otherwise modified from time to time.

 

9.          This Agreement may be executed in any number of counterparts and by different parties hereto in separate counterparts and may be delivered by facsimile or pdf electronic transmission, each of which when so executed and delivered shall be deemed to be an original and effective as a manually signed counterpart and all of which when taken together shall constitute but one and the same agreement.

 

4

 

10.         The rights and obligations of all parties hereto shall be governed by the laws of the State of New York, without regard to principles of conflicts of laws (other than Sections 5-1401 and 5-1402 of the New York General Obligations Law).

 

11.         EACH PARTY TO THIS AGREEMENT HEREBY EXPRESSLY WAIVES ANY RIGHT TO TRIAL BY JURY OF ANY CLAIM, DEMAND, ACTION OR CAUSE OF ACTION (A) ARISING UNDER THIS AGREEMENT OR ANY OTHER INSTRUMENT, DOCUMENT OR AGREEMENT EXECUTED OR DELIVERED IN CONNECTION HEREWITH, OR (B) IN ANY WAY CONNECTED WITH OR RELATED OR INCIDENTAL TO THE DEALINGS OF THE PARTIES HERETO OR ANY OF THEM WITH RESPECT TO THIS AGREEMENT OR ANY OTHER INSTRUMENT, DOCUMENT OR AGREEMENT EXECUTED OR DELIVERED IN CONNECTION HEREWITH, OR THE TRANSACTIONS RELATED HERETO OR THERETO IN EACH CASE WHETHER NOW EXISTING OR HEREAFTER ARISING, AND WHETHER SOUNDING IN CONTRACT OR TORT OR OTHERWISE AND EACH PARTY HEREBY CONSENTS THAT ANY SUCH CLAIM, DEMAND, ACTION OR CAUSE OF ACTION SHALL BE DECIDED BY COURT TRIAL WITHOUT A JURY, AND THAT ANY PARTY TO THIS AGREEMENT MAY FILE AN ORIGINAL COUNTERPART OR A COPY OF THIS SECTION WITH ANY COURT AS WRITTEN EVIDENCE OF THE CONSENTS OF THE PARTIES HERETO TO THE WAIVER OF THEIR RIGHT TO TRIAL BY JURY.

 

[The remainder of this page is intentionally left blank.]

 

 

5

 

IN WITNESS WHEREOF, the duly authorized officers of the parties to this Agreement have executed this Agreement as of the date first written above.

 

  BORROWERS:
     
  ULTRALIFE CORPORATION
     
     
  By: /s/ Michael E. Manna
  Name: Michael E. Manna
  Title: President and Chief Executive Officer
     
  SOUTHWEST ELECTRONIC ENERGY
  CORPORATION
     
     
  By: /s/ Michael E. Manna
  Name: Michael E. Manna
  Title: President
     
  CLB, INC.
     
     
  By: /s/ Michael E. Manna
  Name: Michael E. Manna
  Title: President
     
  ULTRALIFE EXCELL HOLDING CORP.
     
     
  By: /s/ Michael E. Manna
  Name: Michael E. Manna
  Title: President
     
  ULTRALIFE CANADA HOLDING CORP.
     
     
  By: /s/ Michael E. Manna
  Name: Michael E. Manna
  Title: President
     
  EXCELL BATTERY CORPORATION USA
     
     
  By: /s/ Michael E. Manna
  Name: Michael E. Manna
  Title: President

 

 

[Signature Page to Fourth Amendment Agreement – Key/Ultralife]


 

  OTHER CREDIT PARTIES:
     
  EXCELL BATTERY CANADA ULC
     
     
  By: /s/ Michael E. Manna
  Name: Michael E. Manna
  Title: President and Chief Executive Officer

 

 

[Continuation of Signature Page to Fourth Amendment Agreement – Key/Ultralife]


 

  AGENT AND THE LENDERS:
     
  KEYBANK NATIONAL ASSOCIATION,
  as Agent and as a Lender
     
     
  By: /s/ Peter F. Leonard 
  Name: Peter F. Leonard
  Title: Senior Vice President

 

 

[Continuation of Signature Page to Fourth Amendment Agreement – Key/Ultralife]


 

FOURTH AMENDMENT AGREEMENT KEY/ ULTRALIFE

 

 

 

Exhibit 31.1

 

I, Michael E. Manna, certify that:

 

1.

I have reviewed this quarterly report on Form 10-Q of Ultralife Corporation;

 

2.

Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of the circumstances under which such statements were made, not misleading with respect to the period covered by this report;

 

3.

Based on my knowledge, the financial statements, and other financial information included in this report, fairly present in all material respects the financial condition, results of operations and cash flows of the registrant as of, and for, the periods presented in this report;

 

4.

The registrant’s other certifying officer(s) and I are responsible for establishing and maintaining disclosure controls and procedures (as defined in Exchange Act Rules 13a-15(e) and 15d-15(e)) and internal control over financial reporting (as defined in Exchange Act Rules 13a-15(f) and 15d-15(f)) for the registrant and have:

 

 

a)

Designed such disclosure controls and procedures, or caused such disclosure controls and procedures to be designed under our supervision, to ensure that material information relating to the registrant, including its consolidated subsidiaries, is made known to us by others within those entities, particularly during the period in which this report is being prepared;

 

 

b)

Designed such internal control over financial reporting, or caused such internal control over financial reporting to be designed under our supervision, to provide reasonable assurance regarding the reliability of financial reporting and the preparation of financial statements for external purposes in accordance with generally accepted accounting principles;

 

 

c)

Evaluated the effectiveness of the registrant’s disclosure controls and procedures and presented in this report our conclusions about the effectiveness of the disclosure controls and procedures, as of the end of the period covered by this report based on such evaluation; and

 

 

d)

Disclosed in this report any change in the registrant’s internal control over financial reporting that occurred during the registrant’s most recent fiscal quarter (the registrant’s fourth fiscal quarter in the case of an annual report) that has materially affected, or is reasonably likely to materially affect, the registrant’s internal control over financial reporting; and

 

5.

The registrant’s other certifying officer(s) and I have disclosed, based on our most recent evaluation of internal control over financial reporting, to the registrant’s auditors and the audit committee of the registrant’s board of directors (or persons performing the equivalent functions):

 

 

a)

All significant deficiencies and material weaknesses in the design or operation of internal control over financial reporting which are reasonably likely to adversely affect the registrant’s ability to record, process, summarize and report financial information; and

 

 

b)

Any fraud, whether or not material, that involves management or other employees who have a significant role in the registrant’s internal control over financial reporting.

 

 

 

Date: July 25, 2024

By:

/s/ Michael E. Manna  
   

 

  Michael E. Manna  
   

 

  President and Chief Executive Officer  

 

 

Exhibit 31.2

 

I, Philip A. Fain, certify that:

 

1.

I have reviewed this quarterly report on Form 10-Q of Ultralife Corporation;

 

2.

Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of the circumstances under which such statements were made, not misleading with respect to the period covered by this report;

 

3.

Based on my knowledge, the financial statements, and other financial information included in this report, fairly present in all material respects the financial condition, results of operations and cash flows of the registrant as of, and for, the periods presented in this report;

 

4.

The registrant’s other certifying officer(s) and I are responsible for establishing and maintaining disclosure controls and procedures (as defined in Exchange Act Rules 13a-15(e) and 15d-15(e)) and internal control over financial reporting (as defined in Exchange Act Rules 13a-15(f) and 15d-15(f)) for the registrant and have:

 

 

a)

Designed such disclosure controls and procedures, or caused such disclosure controls and procedures to be designed under our supervision, to ensure that material information relating to the registrant, including its consolidated subsidiaries, is made known to us by others within those entities, particularly during the period in which this report is being prepared;

 

 

b)

Designed such internal control over financial reporting, or caused such internal control over financial reporting to be designed under our supervision, to provide reasonable assurance regarding the reliability of financial reporting and the preparation of financial statements for external purposes in accordance with generally accepted accounting principles;

 

 

c)

Evaluated the effectiveness of the registrant’s disclosure controls and procedures and presented in this report our conclusions about the effectiveness of the disclosure controls and procedures, as of the end of the period covered by this report based on such evaluation; and

 

 

d)

Disclosed in this report any change in the registrant’s internal control over financial reporting that occurred during the registrant’s most recent fiscal quarter (the registrant’s fourth fiscal quarter in the case of an annual report) that has materially affected, or is reasonably likely to materially affect, the registrant’s internal control over financial reporting; and

 

5.

The registrant’s other certifying officer(s) and I have disclosed, based on our most recent evaluation of internal control over financial reporting, to the registrant’s auditors and the audit committee of the registrant’s board of directors (or persons performing the equivalent functions):

 

 

a)

All significant deficiencies and material weaknesses in the design or operation of internal control over financial reporting which are reasonably likely to adversely affect the registrant’s ability to record, process, summarize and report financial information; and

 

 

b)

Any fraud, whether or not material, that involves management or other employees who have a significant role in the registrant’s internal control over financial reporting.

 

 

 

Date: July 25, 2024

By: /s/

Philip A. Fain

 
       

Philip A. Fain

 
       

Chief Financial Officer and Treasurer

 

 

 

Exhibit 32

 

 

 

Section 1350 Certification

 

Pursuant to 18 U.S.C. Section 1350, as adopted pursuant to Section 906 of the Sarbanes-Oxley Act of 2002 (“Section 906”), Michael E. Manna and Philip A. Fain, the President and Chief Executive Officer and Chief Financial Officer and Treasurer, respectively, of Ultralife Corporation, certify that (i) the Quarterly Report on Form 10-Q for the quarter ended June 30, 2024 fully complies with the requirements of Section 13(a) or 15(d) of the Securities Exchange Act of 1934 and (ii) the information contained in such report fairly presents, in all material respects, the financial condition and results of operations of Ultralife Corporation.

 

A signed original of this written statement required by Section 906 has been provided to Ultralife Corporation and will be retained by Ultralife Corporation and furnished to the Securities and Exchange Commission or its staff upon request.

 

    By: /s/ Michael E. Manna  
 

Date: July 25, 2024

     Michael E. Manna  
        President and Chief Executive Officer  
           
           
 

Date: July 25, 2024

By: /s/ Philip A. Fain  
        Philip A. Fain  
        Chief Financial Officer and Treasurer  

 

 
v3.24.2
Document And Entity Information - shares
6 Months Ended
Jun. 30, 2024
Jul. 22, 2024
Document Information [Line Items]    
Document Type 10-Q  
Document Quarterly Report true  
Document Period End Date Jun. 30, 2024  
Document Transition Report false  
Entity File Number 0-20852  
Entity Registrant Name ULTRALIFE CORPORATION  
Entity Incorporation, State or Country Code DE  
Entity Address, Address Line One 2000 Technology Parkway  
Entity Address, City or Town Newark  
Entity Address, State or Province NY  
Entity Address, Postal Zip Code 14513  
Entity Tax Identification Number 16-1387013  
City Area Code 315  
Local Phone Number 332-7100  
Title of 12(b) Security Common Stock, $0.10 par value per share  
Trading Symbol ULBI  
Security Exchange Name NASDAQ  
Entity Current Reporting Status Yes  
Entity Interactive Data Current Yes  
Entity Filer Category Non-accelerated Filer  
Entity Small Business true  
Entity Emerging Growth Company false  
Entity Shell Company false  
Entity Common Stock, Shares Outstanding (in shares)   16,623,347
Entity Central Index Key 0000875657  
Current Fiscal Year End Date --12-31  
Document Fiscal Year Focus 2024  
Document Fiscal Period Focus Q2  
Amendment Flag false  
v3.24.2
Consolidated Balance Sheets (Current Period Unaudited) - USD ($)
$ in Thousands
Jun. 30, 2024
Dec. 31, 2023
Current assets:    
Cash $ 6,690 $ 10,278
Trade accounts receivable, net of allowance for expected credit losses of $296 and $300, respectively 31,055 31,761
Inventories, net 41,392 42,215
Prepaid expenses and other current assets 4,650 5,949
Total current assets 83,787 90,203
Property, plant and equipment, net 20,281 21,117
Goodwill 37,510 37,571
Other intangible assets, net 14,646 15,107
Deferred income taxes, net 9,088 10,567
Other noncurrent assets 4,505 3,711
Total assets 169,817 178,276
Current liabilities:    
Accounts payable 9,691 11,336
Current portion of long-term debt 2,000 2,000
Accrued compensation and related benefits 2,312 3,115
Accrued expenses and other current liabilities 6,570 7,279
Total current liabilities 20,573 23,730
Long-term debt 9,978 23,624
Deferred income taxes 1,642 1,714
Other noncurrent liabilities 4,279 3,781
Total liabilities 36,472 52,849
Commitments and Contingencies  
Stockholders’ equity:    
Preferred stock – par value $.10 per share; authorized 1,000,000 shares; none issued 0 0
Common stock – par value $.10 per share; authorized 40,000,000 shares; issued – 21,059,461 shares at June 30, 2024 and 20,783,607 shares at December 31, 2023; outstanding – 16,623,347 shares at June 30, 2024 and 16,347,493 shares at December 31, 2023 2,106 2,078
Capital in excess of par value 191,388 189,160
Accumulated deficit (34,894) (40,754)
Accumulated other comprehensive loss (3,895) (3,660)
Treasury stock - at cost; 4,436,114 shares at June 30, 2024 and 4,436,114 shares at December 31, 2023 (21,492) (21,492)
Total Ultralife Corporation equity 133,213 125,332
Non-controlling interest 132 95
Total stockholders’ equity 133,345 125,427
Total liabilities and stockholders’ equity $ 169,817 $ 178,276
v3.24.2
Consolidated Balance Sheets (Current Period Unaudited) (Parentheticals) - USD ($)
$ in Thousands
Jun. 30, 2024
Dec. 31, 2023
Trade accounts receivable, allowance for doubtful accounts $ 296 $ 300
Preferred stock, par value (in dollars per share) $ 0.1 $ 0.1
Preferred Stock, Shares Authorized (in shares) 1,000,000 1,000,000
Preferred Stock, Shares Issued (in shares) 0 0
Common stock, par value (in dollars per share) $ 0.1 $ 0.1
Common Stock, Shares Authorized (in shares) 40,000,000 40,000,000
Common stock, shares issued (in shares) 21,059,461 20,783,607
Common stock, shares outstanding (in shares) 16,623,347 16,347,493
Treasury Stock, Common, Shares (in shares) 4,436,114 4,436,114
v3.24.2
Consolidated Statements of Income and Comprehensive Income (Unaudited) - USD ($)
shares in Thousands, $ in Thousands
3 Months Ended 6 Months Ended
Jun. 30, 2024
Jun. 30, 2023
Jun. 30, 2024
Jun. 30, 2023
Revenues $ 42,983 $ 42,692 $ 84,910 $ 74,608
Cost of products sold 31,420 32,104 61,877 56,584
Gross profit 11,563 10,588 23,033 18,024
Operating expenses:        
Research and development 1,997 1,778 3,753 3,810
Selling, general and administrative 5,649 5,145 11,300 10,523
Total operating expenses 7,646 6,923 15,053 14,333
Operating income 3,917 3,665 7,980 3,691
Interest and financing expense (418) (440) (938) (864)
Miscellaneous income 347 1,498 411 1,428
Total other (expense) income (71) 1,058 (527) 564
Income before income taxes 3,846 4,723 7,453 4,255
Income tax provision 853 1,375 1,556 1,242
Net income 2,993 3,348 5,897 3,013
Net income attributable to non-controlling interest 24 8 37 19
Net income attributable to Ultralife Corporation 2,969 3,340 5,860 2,994
Other comprehensive loss:        
Foreign currency translation adjustments (3) (293) (235) (96)
Comprehensive income attributable to Ultralife Corporation $ 2,966 $ 3,047 $ 5,625 $ 2,898
Net income per share attributable to Ultralife common stockholders – basic (in dollars per share) $ 0.21 $ 0.03 $ 0.21 $ 0.21
Net income per share attributable to Ultralife common stockholders – diluted (in dollars per share) $ 0.21 $ 0.03 $ 0.21 $ 0.21
Weighted average shares outstanding – basic (in shares) 16,568 16,141 16,482 16,138
Potential common shares (in shares) 257 3 179 3
Weighted average shares outstanding - diluted (in shares) 16,825 16,144 16,661 16,141
v3.24.2
Consolidated Statements of Cash Flows - USD ($)
$ in Thousands
6 Months Ended
Jun. 30, 2024
Jun. 30, 2023
OPERATING ACTIVITIES:    
Net income $ 5,897 $ 3,013
Adjustments to reconcile net income to net cash provided by operating activities:    
Depreciation 1,529 1,522
Amortization of intangible assets 455 436
Amortization of financing fees 32 32
Stock-based compensation 320 293
Deferred income taxes 1,394 888
Changes in operating assets and liabilities:    
Accounts receivable 654 (803)
Inventories 717 (4,882)
Prepaid expenses and other assets 404 (526)
Accounts payable and other liabilities (2,558) 413
Net cash used in operating activities 8,844 386
INVESTING ACTIVITIES:    
Purchases of property, plant and equipment (732) (1,013)
Net cash used in investing activities (732) (1,013)
FINANCING ACTIVITIES:    
Proceeds from exercise of stock options 1,936 62
Net cash (used in) provided by financing activities (11,743) 3,362
Effect of exchange rate changes on cash 43 (165)
(DECREASE) INCREASE IN CASH (3,588) 2,570
Cash, Beginning of period 10,278 5,713
Cash, End of period 6,690 8,283
Revolving Credit Facility [Member]    
FINANCING ACTIVITIES:    
(Payments) borrowings on revolving credit facility (12,679) 4,300
Term Loan Facility [Member]    
FINANCING ACTIVITIES:    
Payments on term loan facility $ (1,000) $ (1,000)
v3.24.2
Consolidated Statements of Changes in Stockholders' Equity (Unaudited) - USD ($)
$ in Thousands
Common Stock [Member]
Additional Paid-in Capital [Member]
AOCI Including Portion Attributable to Noncontrolling Interest [Member]
Retained Earnings [Member]
Treasury Stock, Common [Member]
Noncontrolling Interest [Member]
Total
Balance (in shares) at Dec. 31, 2022 20,570,710            
Balance at Dec. 31, 2022 $ 2,057 $ 187,405 $ (3,750) $ (47,951) $ (21,484) $ 126 $ 116,403
Net income       2,994   19 3,013
Stock Issued During Period, Value, Stock Options Exercised (in shares) 15,335            
Stock option exercises $ 2 60     0   62
Stock-based compensation – stock options   291         291
Stock-based compensation – restricted stock   2         2
Foreign currency translation adjustments adjustments     (96)       (96)
Balance (in shares) at Jun. 30, 2023 20,586,045            
Balance at Jun. 30, 2023 $ 2,059 187,758 (3,846) (44,957) (21,484) 145 119,675
Balance (in shares) at Mar. 31, 2023 20,570,710            
Balance at Mar. 31, 2023 $ 2,057 187,544 (3,553) (48,297) (21,484) 137 116,404
Net income       3,340   8 3,348
Stock Issued During Period, Value, Stock Options Exercised (in shares) 15,335            
Stock option exercises $ 2 60     0   62
Stock-based compensation – stock options   153         153
Stock-based compensation – restricted stock   1         1
Foreign currency translation adjustments adjustments     (293)       (293)
Balance (in shares) at Jun. 30, 2023 20,586,045            
Balance at Jun. 30, 2023 $ 2,059 187,758 (3,846) (44,957) (21,484) 145 $ 119,675
Balance (in shares) at Dec. 31, 2023 20,783,607           16,347,493
Balance at Dec. 31, 2023 $ 2,078 189,160 (3,660) (40,754) (21,492) 95 $ 125,427
Net income       5,860   37 $ 5,897
Stock Issued During Period, Value, Stock Options Exercised (in shares) 275,854           288,675
Stock option exercises $ 28 1,908     0   $ 1,936
Stock-based compensation – stock options   308         308
Stock-based compensation – restricted stock   12         12
Foreign currency translation adjustments adjustments     (235)       $ (235)
Balance (in shares) at Jun. 30, 2024 21,059,461           16,623,347
Balance at Jun. 30, 2024 $ 2,106 191,388 (3,895) (34,894) (21,492) 132 $ 133,345
Balance (in shares) at Mar. 31, 2024 20,887,446            
Balance at Mar. 31, 2024 $ 2,089 189,995 (3,892) (37,863) (21,492) 108 128,945
Net income       2,969   24 2,993
Stock Issued During Period, Value, Stock Options Exercised (in shares) 172,015            
Stock option exercises $ 17 1,234     0   1,251
Stock-based compensation – stock options   152         152
Stock-based compensation – restricted stock   7         7
Foreign currency translation adjustments adjustments     (3)       $ (3)
Balance (in shares) at Jun. 30, 2024 21,059,461           16,623,347
Balance at Jun. 30, 2024 $ 2,106 $ 191,388 $ (3,895) $ (34,894) $ (21,492) $ 132 $ 133,345
v3.24.2
Note 1 - Basis of Presentation
6 Months Ended
Jun. 30, 2024
Notes to Financial Statements  
Business Description and Accounting Policies [Text Block]

1.

BASIS OF PRESENTATION

 

The accompanying unaudited consolidated financial statements of Ultralife Corporation and its subsidiaries (the “Company” or “Ultralife”) have been prepared in accordance with generally accepted accounting principles in the United States of America (“GAAP”) for interim financial information and with the instructions to Rule 8-03 of Regulation S-X. Accordingly, they do not include all the information and notes for complete financial statements. In the opinion of management, all adjustments (consisting of normal recurring accruals and adjustments) considered necessary for a fair presentation of the consolidated financial statements have been included. Results for interim periods should not be considered indicative of results to be expected for a full year. Reference should be made to the consolidated financial statements and related notes thereto contained in our Form 10-K for the year ended December 31, 2023.

 

The December 31, 2023 consolidated balance sheet information referenced herein was derived from audited financial statements but does not include all disclosures required by GAAP.

 

Certain items previously reported in specific financial statement captions have been reclassified to conform to the current presentation.

 

Recent Accounting Guidance Not Yet Adopted

 

In December 2023, the Financial Accounting Standards Board (“FASB”) issued ASU 2023-09 "Income Taxes (Topics 740): Improvements to Income Tax Disclosures" to expand the disclosure requirements for income taxes, specifically related to the rate reconciliation and income taxes paid. ASU 2023-09 is effective for our annual periods beginning January 1, 2025, with early adoption permitted. We are currently evaluating the potential effect that the updated standard will have on our financial statement disclosures.

v3.24.2
Note 2 - Debt
6 Months Ended
Jun. 30, 2024
Notes to Financial Statements  
Debt Disclosure [Text Block]

2.

DEBT

 

On December 13, 2021, Ultralife, Southwest Electronic Energy Corporation, a Texas corporation and wholly owned subsidiary of Ultralife (“SWE”), CLB, INC., a Texas corporation and wholly owned subsidiary of SWE (“CLB”), Ultralife Excell Holding Corp., a Delaware corporation and wholly owned subsidiary of Ultralife (“UEHC”), Ultralife Canada Holding Corp., a Delaware corporation and wholly owned subsidiary of UEHC (“UCHC”), and Excell Battery Corporation USA, a Texas corporation and wholly owned subsidiary of UEHC (“Excell USA”), as borrowers, entered into the Second Amendment Agreement with KeyBank National Association (“KeyBank” or the “Bank”), as lender and administrative agent, to amend the Credit and Security Agreement dated May 31, 2017 as amended by the First Amendment Agreement by and among Ultralife, SWE, CLB and KeyBank dated May 1, 2019 (the “Credit Agreement”). On November 28, 2022, Ultralife, SWE, CLB, UEHC, UCHC, Excell USA, and Excell Battery Canada ULC, a British Columbia unlimited liability corporation and wholly owned subsidiary of UCHC (“Excell Canada”), entered into that certain Third Amendment Agreement with KeyBank, to further amend the Credit Agreement to, among other things, facilitate the joinder of Excell Canada as a guarantor under the Credit Agreement and to replace the LIBOR benchmark thereunder with the Secured Overnight Financing Rate or “SOFR” (the “Third Amendment Agreement”). On June 30, 2024, Ultralife, SWE, CLB, UEHC, Excell USA and Excell Canada entered into that certain Fourth Amendment Agreement with KeyBank to extend the period under which loans may be requested by the Company under the Credit Agreement to May 30, 2028, to increase the “Applicable Margin” used in the calculation of the rate at which interest accrues on outstanding indebtedness under the Credit Agreement and to increase the fee payable on the average daily unused availability under the $30,000 senior secured revolving credit facility (the “Revolving Credit Facility”) which is made available to the Company under the Credit Agreement (the “Fourth Amendment Agreement”, and together with the Third Amendment Agreement, the Second Amendment Agreement and the Credit Agreement, the “Amended Credit Agreement”).

 

The Amended Credit Agreement, among other things, provides for a 5-year, $10,000 senior secured term loan (the “Term Loan Facility”) and extends the term of the Revolving Credit Facility through May 30, 2028. Up to six months prior to May 30, 2028, the Revolving Credit Facility may be increased to $50,000 with the Bank’s concurrence.

 

As of June 30, 2024, the Company had $5,167 outstanding principal on the Term Loan Facility, $2,000 of which is included in current portion of long-term debt on the balance sheet, and $6,902 outstanding on the Revolving Credit Facility. As of June 30, 2024, total unamortized debt issuance costs of $91, including placement, renewal and legal fees associated with the Amended Credit Agreement, are classified as a reduction of long-term debt on the balance sheet. Debt issuance costs are amortized to interest expense over the term of the Amended Credit Facilities.

 

The remaining availability under the Revolving Credit Facility is subject to certain borrowing base limits based on trade receivables and inventories.

 

The Company is required to repay the borrowings under the Term Loan Facility in equal consecutive monthly payments commencing on February 1, 2022, in arrears, together with applicable interest. All unpaid principal and accrued and unpaid interest with respect to the Term Loan Facility is due and payable in full on January 1, 2027. All unpaid principal and accrued and unpaid interest with respect to the Revolving Credit Facility is due and payable in full on May 30, 2028. The Company may voluntarily prepay principal amounts outstanding at any time subject to certain restrictions.

 

In addition to the customary affirmative and negative covenants, the Company must maintain a consolidated senior leverage ratio, as defined in the Amended Credit Agreement, of equal to or less than 3.5 to 1.0 for the fiscal quarters ending December 31, 2022 and March 31, 2023, and equal to or less than 3.0 to 1.0 for the fiscal quarters ending June 30, 2023 and thereafter. The Company was in full compliance with its covenants under the Amended Credit Agreement as of June 30, 2024.

 

Borrowings under the Amended Credit Facilities are secured by substantially all the assets of the Company and its subsidiaries.

 

Under the Amended Credit Agreement, interest accrues on outstanding indebtedness under the Amended Credit Facilities at the Daily Simple SOFR Rate, plus an index spread adjustment of 0.10%, plus the applicable margin. Upon the effectiveness of the Fourth Amendment Agreement, the applicable margin ranges from 210 to 240 basis points and is determined based on the Company’s senior leverage ratio.

 

In addition, the Company must pay a fee of 0.20% to 0.30% based on the average daily unused availability under the Revolving Credit Facility.

 

Payments must be made by the Company to the extent borrowings exceed the maximum amount then permitted to be drawn on the Amended Credit Facilities and from the proceeds of certain transactions. Upon the occurrence of an event of default, the outstanding obligations may be accelerated, and the Bank will have other customary remedies including resort to the security interest the Company provided to the Bank.

 

Future minimum principal repayment obligations on our Amended Credit Facilities as of June 30, 2024 are as follows:

 

2024

 

$

1,000  

2025

    2,000  

2026

    2,000  

2027

    167  

2028

    6,902  

Total

  $ 12,069  

 

v3.24.2
Note 3 - Earnings Per Share
6 Months Ended
Jun. 30, 2024
Notes to Financial Statements  
Earnings Per Share [Text Block]

3.

EARNINGS PER SHARE

 

Basic earnings (loss) per share (“EPS”) is computed by dividing net income (loss) attributable to Ultralife by the weighted average shares outstanding during the period. Diluted EPS includes the dilutive effect of securities, if any, and is calculated using the treasury stock method.

 

For the three-month period ended June 30, 2024, there were 873,898 outstanding stock options and 5,229 unvested restricted stock awards included in the calculation of diluted weighted average shares outstanding, as such securities were dilutive, resulting in 257,068 potential common shares included in the calculation of diluted EPS. For the comparable three-month period ended June 30, 2023, 4,166 outstanding stock options and 2,500 unvested restricted stock awards were included in the calculation of diluted weighted average shares outstanding, as such securities were dilutive, resulting in 2,334 potential common shares included in the calculation of diluted EPS. For the three-month period ended June 30, 2023, there were 1,289,862 outstanding stock options not included in the calculation of diluted weighted average shares outstanding as the effect would be anti-dilutive.

 

For the six-month period ended June 30, 2024, there were 795,898 outstanding stock options and 5,229 unvested restricted stock awards included in the calculation of diluted weighted average shares outstanding, resulting in 179,112 potential common shares included in the calculation of diluted EPS. For the comparable six-month period ended June 30, 2023, there were no outstanding stock options and 2,500 unvested restricted stock awards included in the calculation of diluted weighted average shares outstanding, resulting in 2,157 potential common shares included in the calculation of diluted EPS. There were 78,000 and 1,294,028 outstanding stock options for the six-month periods ended June 30, 2024 and 2023, respectively, not included in the calculation of diluted weighted average shares outstanding as the effect would be anti-dilutive.

v3.24.2
Note 4 - Supplemental Balance Sheet Information
6 Months Ended
Jun. 30, 2024
Notes to Financial Statements  
Supplemental Balance Sheet Disclosures [Text Block]

4.

SUPPLEMENTAL BALANCE SHEET INFORMATION

 

Fair Value Measurements and Disclosures

 

The fair value of financial instruments approximated their carrying values at June 30, 2024 and December 31, 2023. The fair value of cash, accounts receivable, accounts payable, accrued liabilities, and the current portion of long-term debt approximates carrying value due to the short-term nature of these instruments.

 

Cash

 

The composition of the Company’s cash was as follows:

 

   

June 30,

   

December 31,

 
   

2024

   

2023

 

Cash

  $ 6,690     $ 10,196  

Restricted cash

    -       82  

Total

  $ 6,690     $ 10,278  

 

As December 31, 2023, restricted cash of $82 represented euro-denominated deposits withheld by the Dutch tax authorities and third-party VAT representatives in connection with a previously utilized logistics arrangement in the Netherlands. During the period ended June 30, 2024, the deposits were returned to the Company and no longer restricted. As of June 30, 2024, there was no cash classified as restricted cash. Restricted cash as of December 31, 2023 is included as a component of the cash balance for purposes of the consolidated statements of cash flows.

 

Inventories, Net

 

Inventories are stated at the lower of cost or net realizable value, net of obsolescence reserves, with cost determined under the first-in, first-out (FIFO) method. The composition of inventories, net was:

 

   

June 30,

   

December 31,

 
   

2024

   

2023

 

Raw materials

  $ 29,848     $ 29,098  

Work in process

    3,185       3,187  

Finished goods

    8,359       9,930  

Total

  $ 41,392     $ 42,215  

 

Property, Plant and Equipment, Net

 

Major classes of property, plant and equipment consisted of the following:

 

   

June 30,

   

December 31,

 
   

2024

   

2023

 

Land

  $ 1,273     $ 1,273  

Buildings and leasehold improvements

    16,064       15,998  

Machinery and equipment

    57,494       57,584  

Furniture and fixtures

    2,809       2,845  

Computer hardware and software

    7,816       7,868  

Construction in process

    1,846       2,033  
      87,302       87,601  

Less: Accumulated depreciation

    (67,021 )     (66,484 )

Property, plant and equipment, net

  $ 20,281     $ 21,117  

 

 

Depreciation expense for property, plant and equipment was as follows:

 

    Three-month period ended    

Six-month period ended

 
   

June 30,

   

June 30,

   

June 30,

   

June 30,

 
   

2024

   

2023

   

2024

   

2023

 

Depreciation expense

  $ 789     $ 760     $ 1,529     $ 1,522  

 

 

Goodwill

 

The following table summarizes the goodwill activity by segment for the six-month period ended June 30, 2024.

 

    Battery &

Energy

   

Communications

         
   

Products

   

Systems

   

Total

 

Balance – December 31, 2023

  $ 26,078     $ 11,493     $ 37,571  

Effect of foreign currency translation

    (61 )     -       (61 )

Balance – June 30, 2024

  $ 26,017     $ 11,493     $ 37,510  

 

Other Intangible Assets, Net

 

The composition of other intangible assets was:

 

   

at June 30, 2024

 
           

Accumulated

         
   

Cost

   

Amortization

   

Net

 

Customer relationships

  $ 13,087     $ 6,956     $ 6,131  

Patents and technology

    5,603       5,378       225  

Trade names

    4,647       703       3,944  

Trademarks

    3,399       -       3,399  

Other

    1,500       553       947  

Total other intangible assets

  $ 28,236     $ 13,590     $ 14,646  

 

 

   

at December 31, 2023

 
           

Accumulated

         
   

Cost

   

Amortization

   

Net

 

Customer relationships

  $ 13,092     $ 6,656     $ 6,436  

Patents and technology

    5,606       5,322       284  

Trade names

    4,647       647       4,000  

Trademarks

    3,402       -       3,402  

Other

    1,500       515       985  

Total other intangible assets

  $ 28,247     $ 13,140     $ 15,107  

 

The change in the cost of total intangible assets from December 31, 2023 to June 30, 2024 is the effect of foreign currency translations.

 

Amortization expense for other intangible assets was as follows:

 

   

Three-month period ended

   

Six-month period ended

 
   

June 30,

   

June 30,

   

June 30,

   

June 30,

 
   

2024

   

2023

   

2024

   

2023

 

Amortization included in:

                               

Selling, general and administrative

  $ 202     $ 203     $ 405     $ 388  

Research and development

    25       24       50       48  

Total amortization expense

  $ 227     $ 227     $ 455     $ 436  

 

v3.24.2
Note 5 - Stock-based Compensation
6 Months Ended
Jun. 30, 2024
Notes to Financial Statements  
Shareholders' Equity and Share-Based Payments [Text Block]

5.

STOCK-BASED COMPENSATION

 

We recorded non-cash stock compensation expense in each period as follows:

 

   

Three-month period ended

   

Six-month period ended

 
   

June 30,

   

June 30,

   

June 30,

   

June 30,

 
   

2024

   

2023

   

2024

   

2023

 

Stock options

  $ 152     $ 153     $ 308     $ 291  

Restricted stock

    7       1       12       2  

Total

  $ 159     $ 154     $ 320     $ 293  

 

We have stock options outstanding from various stock-based employee compensation plans for which we record compensation cost relating to share-based payment transactions in our financial statements. As of June 30, 2024, there was $545 of total unrecognized compensation cost related to outstanding stock options, which is expected to be recognized over a weighted average period of 1.0 years.

 

The following table summarizes stock option activity for the six-month period ended June 30, 2024:

 

   

Number of

Shares

   

Weighted

Average

Exercise

Price

   

Weighted

Average

Remaining Contractual

Term (years)

   

Aggregate

Intrinsic

Value

 

Outstanding at January 1, 2024

    1,250,595     $ 7.10                  

Granted

    3,460       6.84                  

Exercised

    (288,675 )     7.10                  

Forfeited or expired

    (91,482 )   $ 8.79                  

Outstanding at June 30, 2024

    873,898     $ 6.92       4.34     $ 3,231  

Vested and expected to vest at June 30, 2024

    775,281     $ 7.00       4.18     $ 2,805  

Exercisable at June 30, 2024

    417,867     $ 7.56       2.87     $ 1,277  

 

Cash received from stock option exercises under our stock-based compensation plans for the three-month periods ended June 30, 2024 and June 30, 2023 was $1,251 and $62, respectively. Cash received from stock option exercises under our stock-based compensation plans for the six-month periods ended June 30, 2024 and June 30, 2023 was $1,936 and $62, respectively.

 

Restricted stock awards vest in equal annual installments over three (3) years. Unrecognized compensation cost related to unvested restricted shares at June 30, 2024 and June 30, 2023, respectively, was $25 and $1.

 

v3.24.2
Note 6 - Income Taxes
6 Months Ended
Jun. 30, 2024
Notes to Financial Statements  
Income Tax Disclosure [Text Block]

6.

INCOME TAXES

 

Our effective tax rate for the six-month periods ended June 30, 2024 and June 30, 2023 was 20.9% and 29.2%, respectively. The period-over-period change was primarily attributable to the geographic mix of our operating results and the larger impact of discrete adjustments for stock option exercises in the current year.

 

As of December 31, 2023, we have domestic net operating loss (“NOL”) carryforwards of $27,200, which expire 2031 through 2035, and domestic tax credits of $2,900, which expire 2028 through 2043, available to reduce future taxable income. As of June 30, 2024, management has concluded it is more likely than not that these domestic NOL and credit carryforwards will be fully utilized.

 

As of June 30, 2024, for certain past operations in the U.K., we continue to report a valuation allowance for NOL carryforwards of approximately $9,800, nearly all of which can be carried forward indefinitely. Utilization of the net operating losses may be limited due to the change in the past U.K. operation and cannot currently be used to reduce taxable income at our other U.K. subsidiary, Accutronics Ltd. There are no other deferred tax assets related to the past U.K. operations.

 

As of June 30, 2024, we have not recognized a valuation allowance against our other foreign deferred tax assets, as realization is considered to be more likely than not.

 

As of June 30, 2024, the Company maintains its assertion that all foreign earnings will be indefinitely reinvested in those operations, other than earnings generated in the U.K.

 

There were no unrecognized tax benefits related to uncertain tax positions at June 30, 2024 and December 31, 2023.

 

As a result of our operations, we file income tax returns in various jurisdictions including U.S. federal, U.S. state and foreign jurisdictions. We are routinely subject to examination by taxing authorities in these various jurisdictions. Our U.S. tax matters for 2020 thru 2022 remain subject to IRS examination. Our U.S. tax matters for 2001-2002, 2005-2007, 2009, and 2011-2015 also remain subject to IRS examination due to the remaining availability of net operating loss carryforwards generated in those years. Our U.S. tax matters for 2013 thru 2022 remain subject to examination by various state and local tax jurisdictions. Our tax matters for the years 2013 thru 2022 remain subject to examination by the respective foreign tax jurisdiction authorities.

 

v3.24.2
Note 7 - Operating Leases
6 Months Ended
Jun. 30, 2024
Notes to Financial Statements  
Lessee, Operating Leases [Text Block]

7.

OPERATING LEASES

 

The Company has operating leases predominantly for operating facilities. As of June 30, 2024, the remaining lease terms on our operating leases range from approximately less than one (1) year to seven (7) years. Lease terms include renewal options reasonably certain of exercise. There is no transfer of title or option to purchase the leased assets upon expiration. There are no residual value guarantees or material restrictive covenants.

 

The components of lease expense for the current and prior-year comparative periods were as follows:

 

   

Three months ended

   

Six months ended

 
   

June 30, 2024

   

June 30, 2023

   

June 30, 2024

   

June 30, 2023

 

Operating lease cost

  $ 268     $ 239     $ 530     $ 480  

Variable lease cost

    24       29       52       57  

Total lease cost

  $ 292     $ 268     $ 582     $ 537  

 

Supplemental cash flow information related to leases was as follows:

 

   

Six-month period ended June 30,

 
   

2024

   

2023

 

Cash paid for amounts included in the measurement of lease liabilities:

               

Operating cash flows from operating leases

  $ 568     $ 494  

Right-of-use assets obtained in exchange for lease liabilities:

  $ 1,391     $ 310  

 

Supplemental consolidated balance sheet information related to leases was as follows:

 

 

Balance sheet classification

 

June 30,

2024

   

December 31,

2023

 

Assets:

                 

Operating lease right-of-use asset

Other noncurrent assets

  $ 4,325     $ 3,589  
                   

Liabilities:

                 

Current operating lease liability

Accrued expenses and other current liabilities

  $ 1,017     $ 894  

Operating lease liability, net of current portion

Other noncurrent liabilities

    3,285       2,644  

Total operating lease liability

  $ 4,302     $ 3,538  
                   

Weighted-average remaining lease term (years)

    5.1       5.3  
                   

Weighted-average discount rate

    6.8 %     4.5 %

 

Future minimum lease payments as of June 30, 2024 are as follows:

 

Maturity of operating lease liabilities

       

2024

  $ 539  

2025

    1,016  

2026

    942  

2027

    969  

2028

    977  

Thereafter

    624  

Total lease payments

    5,067  

Less: Imputed interest

    (765 )

Present value of remaining lease payments

  $ 4,302  

 

v3.24.2
Note 8 - Commitments and Contingencies
6 Months Ended
Jun. 30, 2024
Notes to Financial Statements  
Commitments and Contingencies Disclosure [Text Block]

8.

COMMITMENTS AND CONTINGENCIES

 

Purchase Commitments

 

As of June 30, 2024, we have made commitments to purchase approximately $779 of production machinery and equipment.

 

Product Warranties

 

We estimate future warranty costs to be incurred for product failure rates, material usage and service costs in the development of our warranty obligations. Estimated future costs are based on actual past experience and are generally estimated as a percentage of sales over the warranty period. Changes in our product warranty liability during the first six months of 2024 and 2023 were as follows:

 

   

Six-month period ended June 30,

 
   

2024

   

2023

 

Accrued warranty obligations – beginning

  $ 547     $ 323  

Accruals for warranties issued

    389       172  

Settlements made

    (147 )     (62 )

Accrued warranty obligations – ending

  $ 789     $ 433  

 

Contingencies and Legal Matters

 

We are subject to legal proceedings and claims that arise from time to time in the normal course of business. We believe that the final disposition of any such matters will not have a material adverse effect on the Company’s financial position, results of operations or cash flows. However, recognizing that legal matters are subject to inherent uncertainties, there exists the possibility that ultimate resolution of these matters could have a material adverse impact on the Company’s financial position, results of operations or cash flows. We are not aware of any such situations at this time.

v3.24.2
Note 9 - Revenue Recognition
6 Months Ended
Jun. 30, 2024
Notes to Financial Statements  
Revenue from Contract with Customer [Text Block]

9.

REVENUE RECOGNITION

 

Revenues are generated from the sale of products. Performance obligations are met and revenue is recognized upon transfer of control to the customer, which is generally upon shipment. When contract terms require transfer of control upon delivery at a customer’s location, revenue is recognized on the date of delivery. For products shipped under vendor-managed inventory arrangements, revenue is recognized and billed when the product is consumed by the customer, at which point control has transferred and there are no further obligations by the Company. Revenue is measured as the amount of consideration we expect to receive in exchange for shipped product. Sales, value-added and other taxes billed and collected from customers are excluded from revenue. Customers, including distributors, do not have a general right of return.

 

Separately priced extended warranty contracts are offered on certain Communications Systems products for a duration of up to eight (8) years. Extended warranties are treated as separate performance obligations and recognized to revenue evenly over the term of the respective contract. Revenue not yet recognized on extended warranty contracts is recorded as deferred revenue on the consolidated balance sheet. For the three-month and six-month periods ended June 30, 2024, revenue recognized on extended warranties was $71 and $143, respectively.

 

As of June 30, 2024, there was deferred revenue on extended warranty contracts of $1,264, comprised of $287 expected to be recognized as revenue within one (1) year and classified as accrued expenses and other current liabilities on our consolidated balance sheet, and $977 expected to be recognized as revenue over the remaining duration of the respective contracts and classified as other noncurrent liabilities on our consolidated balance sheet.

 

As of December 31, 2023, there was deferred revenue on extended warranty contracts of $1,407, comprised of $287 expected to be recognized as revenue within one (1) year and classified as accrued expenses and other current liabilities on our consolidated balance sheet, and $1,120 expected to be recognized as revenue evenly over the remaining duration of the respective contracts and classified as other noncurrent liabilities on our consolidated balance sheet.

 

As of June 30, 2024 and December 31, 2023, the Company had no other unsatisfied performance obligations for contracts with an original expected duration of greater than one year. Pursuant to Topic 606, we have applied the practical expedient with respect to disclosure of the deferral and future expected timing of revenue recognition for transaction price allocated to remaining performance obligations.

v3.24.2
Note 10 - Business Segment Information
6 Months Ended
Jun. 30, 2024
Notes to Financial Statements  
Segment Reporting Disclosure [Text Block]

10.

BUSINESS SEGMENT INFORMATION

 

We report our results in two operating segments: Battery & Energy Products and Communications Systems. The Battery & Energy Products segment includes Lithium 9-volt, cylindrical and various other non-rechargeable batteries, in addition to rechargeable batteries, uninterruptable power supplies, charging systems and accessories. The Communications Systems segment includes RF amplifiers, power supplies, cable and connector assemblies, amplified speakers, equipment mounts, case equipment, man-portable systems, integrated communication systems for fixed or vehicle applications and communications and electronics systems design. We believe that reporting performance at the gross profit level is the best indicator of segment performance. 

 

Three-month period ended June 30, 2024:

 

   

Battery &

Energy

Products

   

Communications

Systems

   

Corporate

   

Total

 

Revenues

  $ 36,683     $ 6,300     $ -     $ 42,983  

Segment contribution

    9,953       1,610       (7,646 )     3,917  

Other expense

                    (71 )     (71 )

Income tax provision

                    (853 )     (853 )

Non-controlling interest

                    (24 )     (24 )

Net income attributable to Ultralife

                          $ 2,969  

 

Three-month period ended June 30, 2023:

 

   

Battery &

Energy

Products

   

Communications

Systems

   

Corporate

   

Total

 

Revenues

  $ 33,861     $ 8,831     $ -     $ 42,692  

Segment contribution

    7,543       3,045       (6,923 )     3,665  

Other income

                    1,058       1,058  

Income tax provision

                    (1,375 )     (1,375 )

Non-controlling interest

                    (8 )     (8 )

Net income attributable to Ultralife

                          $ 3,340  

 

Six-month period ended June 30, 2024:

 

   

Battery &

Energy

Products

   

Communications

Systems

   

Corporate

   

Total

 

Revenues

  $ 71,672     $ 13,238     $ -     $ 84,910  

Segment contribution

    18,939       4,094       (15,053 )     7,980  

Other expense

                    (527 )     (527 )

Income tax provision

                    (1,556 )     (1,556 )

Non-controlling interest

                    (37 )     (37 )

Net income attributable to Ultralife

                          $ 5,860  

 

Six-month period ended June 30, 2023:

 

   

Battery &

Energy

Products

   

Communications

Systems

   

Corporate

   

Total

 

Revenues

  $ 62,331     $ 12,277     $ -     $ 74,608  

Segment contribution

    14,055       3,969       (14,333 )     3,691  

Other income

                    564       564  

Income tax provision

                    (1,242 )     (1,242 )

Non-controlling interest

                    (19 )     (19 )

Net income attributable to Ultralife

                          $ 2,994  

 

The following tables disaggregate our business segment revenues by major source and geography.

 

Commercial and Government/Defense Revenue Information:

 

Three-month period ended June 30, 2024:

 

   

Total

Revenue

   

Commercial

   

Government/

Defense

 

Battery & Energy Products

  $ 36,683     $ 27,664     $ 9,019  

Communications Systems

    6,300       -       6,300  

Total

  $ 42,983     $ 27,664     $ 15,319  
              64 %     36 %

 

Three-month period ended June 30, 2023:

 

   

Total

Revenue

   

Commercial

   

Government/

Defense

 

Battery & Energy Products

  $ 33,861     $ 26,950     $ 6,911  

Communications Systems

    8,831       -       8,831  

Total

  $ 42,692     $ 26,950     $ 15,742  
              63 %     37 %

 

Six-month period ended June 30, 2024:

 

   

Total

Revenue

   

Commercial

   

Government/

Defense

 

Battery & Energy Products

  $ 71,672     $ 51,804     $ 19,868  

Communications Systems

    13,238       -       13,238  

Total

  $ 84,910     $ 51,804     $ 33,106  
              61 %     39 %

 

Six-month period ended June 30, 2023:

 

   

Total

Revenue

   

Commercial

   

Government/

Defense

 

Battery & Energy Products

  $ 62,331     $ 49,169     $ 13,162  

Communications Systems

    12,277       -       12,277  

Total

  $ 74,608     $ 49,169     $ 25,439  
              66 %     34 %

 

U.S. and Non-U.S. Revenue Information1:

 

Three-month period ended June 30, 2024:

 

   

Total

Revenue

   

United

States

   

Non-United

States

 

Battery & Energy Products

  $ 36,683     $ 19,412     $ 17,271  

Communications Systems

    6,300       3,987       2,313  

Total

  $ 42,983     $ 23,399     $ 19,584  
              54 %     46 %

 

Three-month period ended June 30, 2023:

 

   

Total

Revenue

   

United

States

   

Non-United

States

 

Battery & Energy Products

  $ 33,861     $ 17,394     $ 16,467  

Communications Systems

    8,831       3,945       4,886  

Total

  $ 42,692     $ 21,339     $ 21,353  
              50 %     50 %

 

Six-month period ended June 30, 2024:

 

   

Total

Revenue

   

United

States

   

Non-United

States

 

Battery & Energy Products

  $ 71,672     $ 39,015     $ 32,657  

Communications Systems

    13,238       8,845       4,393  

Total

  $ 84,910     $ 47,860     $ 37,050  
              56 %     44 %

 

Six-month period ended June 30, 2023:

 

   

Total

Revenue

   

United

States

   

Non-United

States

 

Battery & Energy Products

  $ 62,331     $ 31,162     $ 31,169  

Communications Systems

    12,277       6,822       5,455  

Total

  $ 74,608     $ 37,984     $ 36,624  
              51 %     49 %

 

1 Sales classified to U.S. include shipments to U.S.-based prime contractors which in some cases may serve non-U.S. projects.

 

v3.24.2
Note 2 - Debt (Tables)
6 Months Ended
Jun. 30, 2024
Notes Tables  
Schedule of Maturities of Long-Term Debt [Table Text Block]

2024

 

$

1,000  

2025

    2,000  

2026

    2,000  

2027

    167  

2028

    6,902  

Total

  $ 12,069  
v3.24.2
Note 4 - Supplemental Balance Sheet Information (Tables)
6 Months Ended
Jun. 30, 2024
Notes Tables  
Cash, Cash Equivalents and Investments [Table Text Block]
   

June 30,

   

December 31,

 
   

2024

   

2023

 

Cash

  $ 6,690     $ 10,196  

Restricted cash

    -       82  

Total

  $ 6,690     $ 10,278  
Schedule of Inventory, Current [Table Text Block]
   

June 30,

   

December 31,

 
   

2024

   

2023

 

Raw materials

  $ 29,848     $ 29,098  

Work in process

    3,185       3,187  

Finished goods

    8,359       9,930  

Total

  $ 41,392     $ 42,215  
Property, Plant and Equipment [Table Text Block]
   

June 30,

   

December 31,

 
   

2024

   

2023

 

Land

  $ 1,273     $ 1,273  

Buildings and leasehold improvements

    16,064       15,998  

Machinery and equipment

    57,494       57,584  

Furniture and fixtures

    2,809       2,845  

Computer hardware and software

    7,816       7,868  

Construction in process

    1,846       2,033  
      87,302       87,601  

Less: Accumulated depreciation

    (67,021 )     (66,484 )

Property, plant and equipment, net

  $ 20,281     $ 21,117  
    Three-month period ended    

Six-month period ended

 
   

June 30,

   

June 30,

   

June 30,

   

June 30,

 
   

2024

   

2023

   

2024

   

2023

 

Depreciation expense

  $ 789     $ 760     $ 1,529     $ 1,522  
Schedule of Goodwill [Table Text Block]
    Battery &

Energy

   

Communications

         
   

Products

   

Systems

   

Total

 

Balance – December 31, 2023

  $ 26,078     $ 11,493     $ 37,571  

Effect of foreign currency translation

    (61 )     -       (61 )

Balance – June 30, 2024

  $ 26,017     $ 11,493     $ 37,510  
Schedule of Finite-Lived Intangible Assets [Table Text Block]
   

at June 30, 2024

 
           

Accumulated

         
   

Cost

   

Amortization

   

Net

 

Customer relationships

  $ 13,087     $ 6,956     $ 6,131  

Patents and technology

    5,603       5,378       225  

Trade names

    4,647       703       3,944  

Trademarks

    3,399       -       3,399  

Other

    1,500       553       947  

Total other intangible assets

  $ 28,236     $ 13,590     $ 14,646  
   

at December 31, 2023

 
           

Accumulated

         
   

Cost

   

Amortization

   

Net

 

Customer relationships

  $ 13,092     $ 6,656     $ 6,436  

Patents and technology

    5,606       5,322       284  

Trade names

    4,647       647       4,000  

Trademarks

    3,402       -       3,402  

Other

    1,500       515       985  

Total other intangible assets

  $ 28,247     $ 13,140     $ 15,107  
Finite-Lived Intangible Assets Amortization Expense [Table Text Block]
   

Three-month period ended

   

Six-month period ended

 
   

June 30,

   

June 30,

   

June 30,

   

June 30,

 
   

2024

   

2023

   

2024

   

2023

 

Amortization included in:

                               

Selling, general and administrative

  $ 202     $ 203     $ 405     $ 388  

Research and development

    25       24       50       48  

Total amortization expense

  $ 227     $ 227     $ 455     $ 436  
v3.24.2
Note 5 - Stock-based Compensation (Tables)
6 Months Ended
Jun. 30, 2024
Notes Tables  
Disclosure of Share-Based Compensation Arrangements by Share-Based Payment Award [Table Text Block]
   

Three-month period ended

   

Six-month period ended

 
   

June 30,

   

June 30,

   

June 30,

   

June 30,

 
   

2024

   

2023

   

2024

   

2023

 

Stock options

  $ 152     $ 153     $ 308     $ 291  

Restricted stock

    7       1       12       2  

Total

  $ 159     $ 154     $ 320     $ 293  
Share-Based Payment Arrangement, Option, Activity [Table Text Block]
   

Number of

Shares

   

Weighted

Average

Exercise

Price

   

Weighted

Average

Remaining Contractual

Term (years)

   

Aggregate

Intrinsic

Value

 

Outstanding at January 1, 2024

    1,250,595     $ 7.10                  

Granted

    3,460       6.84                  

Exercised

    (288,675 )     7.10                  

Forfeited or expired

    (91,482 )   $ 8.79                  

Outstanding at June 30, 2024

    873,898     $ 6.92       4.34     $ 3,231  

Vested and expected to vest at June 30, 2024

    775,281     $ 7.00       4.18     $ 2,805  

Exercisable at June 30, 2024

    417,867     $ 7.56       2.87     $ 1,277  
v3.24.2
Note 7 - Operating Leases (Tables)
6 Months Ended
Jun. 30, 2024
Notes Tables  
Lease, Cost [Table Text Block]
   

Three months ended

   

Six months ended

 
   

June 30, 2024

   

June 30, 2023

   

June 30, 2024

   

June 30, 2023

 

Operating lease cost

  $ 268     $ 239     $ 530     $ 480  

Variable lease cost

    24       29       52       57  

Total lease cost

  $ 292     $ 268     $ 582     $ 537  
Lessee, Lease, Cash Flow Information [Table Text Block]
   

Six-month period ended June 30,

 
   

2024

   

2023

 

Cash paid for amounts included in the measurement of lease liabilities:

               

Operating cash flows from operating leases

  $ 568     $ 494  

Right-of-use assets obtained in exchange for lease liabilities:

  $ 1,391     $ 310  
Lessee, Lease, Balance Sheet Information [Table Text Block]
 

Balance sheet classification

 

June 30,

2024

   

December 31,

2023

 

Assets:

                 

Operating lease right-of-use asset

Other noncurrent assets

  $ 4,325     $ 3,589  
                   

Liabilities:

                 

Current operating lease liability

Accrued expenses and other current liabilities

  $ 1,017     $ 894  

Operating lease liability, net of current portion

Other noncurrent liabilities

    3,285       2,644  

Total operating lease liability

  $ 4,302     $ 3,538  
                   

Weighted-average remaining lease term (years)

    5.1       5.3  
                   

Weighted-average discount rate

    6.8 %     4.5 %
Lessee, Operating Lease, Liability, to be Paid, Maturity [Table Text Block]

Maturity of operating lease liabilities

       

2024

  $ 539  

2025

    1,016  

2026

    942  

2027

    969  

2028

    977  

Thereafter

    624  

Total lease payments

    5,067  

Less: Imputed interest

    (765 )

Present value of remaining lease payments

  $ 4,302  
v3.24.2
Note 8 - Commitments and Contingencies (Tables)
6 Months Ended
Jun. 30, 2024
Notes Tables  
Schedule of Product Warranty Liability [Table Text Block]
   

Six-month period ended June 30,

 
   

2024

   

2023

 

Accrued warranty obligations – beginning

  $ 547     $ 323  

Accruals for warranties issued

    389       172  

Settlements made

    (147 )     (62 )

Accrued warranty obligations – ending

  $ 789     $ 433  
v3.24.2
Note 10 - Business Segment Information (Tables)
6 Months Ended
Jun. 30, 2024
Notes Tables  
Schedule of Segment Reporting Information, by Segment [Table Text Block]
   

Battery &

Energy

Products

   

Communications

Systems

   

Corporate

   

Total

 

Revenues

  $ 36,683     $ 6,300     $ -     $ 42,983  

Segment contribution

    9,953       1,610       (7,646 )     3,917  

Other expense

                    (71 )     (71 )

Income tax provision

                    (853 )     (853 )

Non-controlling interest

                    (24 )     (24 )

Net income attributable to Ultralife

                          $ 2,969  
   

Battery &

Energy

Products

   

Communications

Systems

   

Corporate

   

Total

 

Revenues

  $ 33,861     $ 8,831     $ -     $ 42,692  

Segment contribution

    7,543       3,045       (6,923 )     3,665  

Other income

                    1,058       1,058  

Income tax provision

                    (1,375 )     (1,375 )

Non-controlling interest

                    (8 )     (8 )

Net income attributable to Ultralife

                          $ 3,340  
   

Battery &

Energy

Products

   

Communications

Systems

   

Corporate

   

Total

 

Revenues

  $ 71,672     $ 13,238     $ -     $ 84,910  

Segment contribution

    18,939       4,094       (15,053 )     7,980  

Other expense

                    (527 )     (527 )

Income tax provision

                    (1,556 )     (1,556 )

Non-controlling interest

                    (37 )     (37 )

Net income attributable to Ultralife

                          $ 5,860  
   

Battery &

Energy

Products

   

Communications

Systems

   

Corporate

   

Total

 

Revenues

  $ 62,331     $ 12,277     $ -     $ 74,608  

Segment contribution

    14,055       3,969       (14,333 )     3,691  

Other income

                    564       564  

Income tax provision

                    (1,242 )     (1,242 )

Non-controlling interest

                    (19 )     (19 )

Net income attributable to Ultralife

                          $ 2,994  
Schedule of Revenues from External Customers by Business Segment Sector [Table Text Block]
   

Total

Revenue

   

Commercial

   

Government/

Defense

 

Battery & Energy Products

  $ 36,683     $ 27,664     $ 9,019  

Communications Systems

    6,300       -       6,300  

Total

  $ 42,983     $ 27,664     $ 15,319  
              64 %     36 %
   

Total

Revenue

   

Commercial

   

Government/

Defense

 

Battery & Energy Products

  $ 33,861     $ 26,950     $ 6,911  

Communications Systems

    8,831       -       8,831  

Total

  $ 42,692     $ 26,950     $ 15,742  
              63 %     37 %
   

Total

Revenue

   

Commercial

   

Government/

Defense

 

Battery & Energy Products

  $ 71,672     $ 51,804     $ 19,868  

Communications Systems

    13,238       -       13,238  

Total

  $ 84,910     $ 51,804     $ 33,106  
              61 %     39 %
   

Total

Revenue

   

Commercial

   

Government/

Defense

 

Battery & Energy Products

  $ 62,331     $ 49,169     $ 13,162  

Communications Systems

    12,277       -       12,277  

Total

  $ 74,608     $ 49,169     $ 25,439  
              66 %     34 %
   

Total

Revenue

   

United

States

   

Non-United

States

 

Battery & Energy Products

  $ 36,683     $ 19,412     $ 17,271  

Communications Systems

    6,300       3,987       2,313  

Total

  $ 42,983     $ 23,399     $ 19,584  
              54 %     46 %
   

Total

Revenue

   

United

States

   

Non-United

States

 

Battery & Energy Products

  $ 33,861     $ 17,394     $ 16,467  

Communications Systems

    8,831       3,945       4,886  

Total

  $ 42,692     $ 21,339     $ 21,353  
              50 %     50 %
   

Total

Revenue

   

United

States

   

Non-United

States

 

Battery & Energy Products

  $ 71,672     $ 39,015     $ 32,657  

Communications Systems

    13,238       8,845       4,393  

Total

  $ 84,910     $ 47,860     $ 37,050  
              56 %     44 %
   

Total

Revenue

   

United

States

   

Non-United

States

 

Battery & Energy Products

  $ 62,331     $ 31,162     $ 31,169  

Communications Systems

    12,277       6,822       5,455  

Total

  $ 74,608     $ 37,984     $ 36,624  
              51 %     49 %
v3.24.2
Note 2 - Debt (Details Textual) - Amended Credit Agreement [Member]
$ in Thousands
Dec. 13, 2021
USD ($)
Jun. 30, 2024
USD ($)
Jun. 30, 2023
Dec. 31, 2022
Debt Issuance Costs, Gross   $ 91    
Revolving Credit Facility [Member]        
Secured Debt, Total   5,167    
Long-Term Line of Credit, Total   6,902    
Maximum Consolidated Senior Leverage Ratio     3 3.5
Revolving Credit Facility [Member] | Minimum [Member]        
Line of Credit Facility, Unused Capacity, Commitment Fee Percentage 0.20%      
Revolving Credit Facility [Member] | Maximum [Member]        
Line of Credit Facility, Unused Capacity, Commitment Fee Percentage 0.30%      
Revolving Credit Facility [Member] | Secured Overnight Financing Rate (SOFR) Overnight Index Swap Rate [Member]        
Debt Instrument, Basis Spread on Variable Rate 0.10%      
Revolving Credit Facility [Member] | Secured Overnight Financing Rate (SOFR) Overnight Index Swap Rate [Member] | Minimum [Member]        
Debt Instrument, Basis Spread on Variable Rate 2.10%      
Revolving Credit Facility [Member] | Secured Overnight Financing Rate (SOFR) Overnight Index Swap Rate [Member] | Maximum [Member]        
Debt Instrument, Basis Spread on Variable Rate 2.40%      
Revolving Credit Facility [Member] | KeyBank [Member]        
Line of Credit Facility, Maximum Borrowing Capacity $ 30,000      
Line Of Credit Facility Maximum Borrowing Capacity Contingent On Bank Approval $ 50,000      
Term Loan Facility [Member] | Long-term Debt, Current Maturities [Member]        
Secured Debt, Total   $ 2,000    
Term Loan Facility [Member] | KeyBank [Member]        
Debt Instrument, Term 5 years      
Debt Instrument, Face Amount $ 10,000      
v3.24.2
Note 2 - Debt - Future Minimum Principal Repayment Obligations (Details) - Revolving Credit Facility [Member] - Amended Credit Agreement [Member]
$ in Thousands
Jun. 30, 2024
USD ($)
2024 $ 1,000
2025 2,000
2026 2,000
2027 167
Thereafter 6,902
Total $ 12,069
v3.24.2
Note 3 - Earnings Per Share (Details Textual) - shares
3 Months Ended 6 Months Ended
Jun. 30, 2024
Jun. 30, 2023
Jun. 30, 2024
Jun. 30, 2023
Dilutive Securities Included in Computation of Earnings Per Share Amount Stock Option 873,898 4,166 795,898 0
Dilutive Securities Included in Computation of Earnings Per Share Amount Restricted Stock 5,229 2,500 5,229 2,500
Incremental Common Shares Attributable to Dilutive Effect of Share-Based Payment Arrangements 257,068 2,334 179,112 2,157
Share-Based Payment Arrangement, Option [Member]        
Antidilutive Securities Excluded from Computation of Earnings Per Share, Amount   1,289,862 78,000 1,294,028
v3.24.2
Note 4 - Supplemental Balance Sheet Information (Details Textual) - USD ($)
$ in Thousands
Jun. 30, 2024
Dec. 31, 2023
Restricted Cash and Cash Equivalents $ 0 $ 82
NETHERLANDS    
Restricted Cash and Cash Equivalents $ 0 $ 82
v3.24.2
Note 4 - Supplemental Balance Sheet Information - Cash and Restricted Cash (Details) - USD ($)
$ in Thousands
Jun. 30, 2024
Dec. 31, 2023
Jun. 30, 2023
Dec. 31, 2022
Cash $ 6,690 $ 10,196    
Restricted cash 0 82    
Total $ 6,690 $ 10,278 $ 8,283 $ 5,713
v3.24.2
Note 4 - Supplemental Balance Sheet Information - Components of Inventory (Details) - USD ($)
$ in Thousands
Jun. 30, 2024
Dec. 31, 2023
Raw materials $ 29,848 $ 29,098
Work in process 3,185 3,187
Finished goods 8,359 9,930
Total $ 41,392 $ 42,215
v3.24.2
Note 4 - Supplemental Balance Sheet Information - Components of Property, Plant and Equipment (Details) - USD ($)
$ in Thousands
3 Months Ended 6 Months Ended
Jun. 30, 2024
Jun. 30, 2023
Jun. 30, 2024
Jun. 30, 2023
Dec. 31, 2023
Property, plant and equipment, gross $ 87,302   $ 87,302   $ 87,601
Depreciation 789 $ 760 1,529 $ 1,522  
Less: Accumulated depreciation (67,021)   (67,021)   (66,484)
Property, plant and equipment, net 20,281   20,281   21,117
Land [Member]          
Property, plant and equipment, gross 1,273   1,273   1,273
Building and Building Improvements [Member]          
Property, plant and equipment, gross 16,064   16,064   15,998
Machinery and Equipment [Member]          
Property, plant and equipment, gross 57,494   57,494   57,584
Furniture and Fixtures [Member]          
Property, plant and equipment, gross 2,809   2,809   2,845
Computer Equipment [Member]          
Property, plant and equipment, gross 7,816   7,816   7,868
Construction in Progress [Member]          
Property, plant and equipment, gross $ 1,846   $ 1,846   $ 2,033
v3.24.2
Note 4 - Supplemental Balance Sheet Information - Summary of Goodwill (Details)
$ in Thousands
6 Months Ended
Jun. 30, 2024
USD ($)
Balance $ 37,571
Effect of foreign currency translation (61)
Balance – March 31, 2024 37,510
Battery & Energy Products Segment [Member]  
Balance 26,078
Effect of foreign currency translation (61)
Balance – March 31, 2024 26,017
Communications Systems Segment [Member]  
Balance 11,493
Effect of foreign currency translation 0
Balance – March 31, 2024 $ 11,493
v3.24.2
Note 4 - Supplemental Balance Sheet Information - Composition of Intangible Assets (Details) - USD ($)
$ in Thousands
Jun. 30, 2024
Dec. 31, 2023
Cost $ 28,236 $ 28,247
Accumulated Amortization 13,590 13,140
Net 14,646 15,107
Customer Relationships [Member]    
Cost 13,087 13,092
Accumulated Amortization 6,956 6,656
Net 6,131 6,436
Patented Technology [Member]    
Cost 5,603 5,606
Accumulated Amortization 5,378 5,322
Net 225 284
Trade Names [Member]    
Cost 4,647 4,647
Accumulated Amortization 703 647
Net 3,944 4,000
Trademarks [Member]    
Cost 3,399 3,402
Accumulated Amortization 0 0
Net 3,399 3,402
Other Intangible Assets [Member]    
Cost 1,500 1,500
Accumulated Amortization 553 515
Net $ 947 $ 985
v3.24.2
Note 4 - Supplemental Balance Sheet Information - Amortization of Intangible Assets (Details) - USD ($)
$ in Thousands
3 Months Ended 6 Months Ended
Jun. 30, 2024
Jun. 30, 2023
Jun. 30, 2024
Jun. 30, 2023
Amortization of intangible assets $ 227 $ 227 $ 455 $ 436
Research and Development Expense [Member]        
Amortization of intangible assets 202 203 405 388
Selling, General and Administrative Expenses [Member]        
Amortization of intangible assets $ 25 $ 24 $ 50 $ 48
v3.24.2
Note 5 - Stock-based Compensation (Details Textual) - USD ($)
$ in Thousands
3 Months Ended 6 Months Ended
Jun. 30, 2024
Jun. 30, 2023
Jun. 30, 2024
Jun. 30, 2023
Proceeds from Stock Options Exercised $ 1,251 $ 62 $ 1,936 $ 62
Share-Based Payment Arrangement, Option [Member]        
Share-Based Payment Arrangement, Nonvested Award, Cost Not yet Recognized, Amount 545   $ 545  
Share-Based Payment Arrangement, Nonvested Award, Cost Not yet Recognized, Period for Recognition     1 year  
Restricted Stock [Member]        
Share-Based Payment Arrangement, Nonvested Award, Cost Not yet Recognized, Amount $ 25 $ 1 $ 25 $ 1
Restricted Stock [Member] | The 2014 Long-term Incentive Plan [Member]        
Share-Based Compensation Arrangement by Share-Based Payment Award, Award Vesting Period     3 years  
v3.24.2
Note 5 - Stock-based Compensation - Non-cash Stock Compensation Expense (Details) - USD ($)
$ in Thousands
3 Months Ended 6 Months Ended
Jun. 30, 2024
Jun. 30, 2023
Jun. 30, 2024
Jun. 30, 2023
Stock-based compensation expense $ 159 $ 154 $ 320 $ 293
Share-Based Payment Arrangement, Option [Member]        
Stock-based compensation expense 152 153 308 291
Restricted Stock [Member]        
Stock-based compensation expense $ 7 $ 1 $ 12 $ 2
v3.24.2
Note 5 - Stock-based Compensation - Stock Option Activity (Details) - USD ($)
$ / shares in Units, $ in Thousands
6 Months Ended
Jun. 30, 2024
Outstanding, shares (in shares) 1,250,595
Outstanding, weighted average exercise price (in dollars per share) $ 7.1
Granted, shares (in shares) 3,460
Granted, weighted average exercise price (in dollars per share) $ 6.84
Exercised, shares (in shares) (288,675)
Exercised, weighted average exercise price (in dollars per share) $ 7.1
Forfeited or expired, shares (in shares) (91,482)
Forfeited or expired, weighted average exercise price (in dollars per share) $ 8.79
Outstanding, shares (in shares) 873,898
Outstanding, weighted average exercise price (in dollars per share) $ 6.92
Outstanding, weighted average remaining contractual term (Year) 4 years 4 months 2 days
Outstanding, aggregate intrinsic value $ 3,231
Vested and expected to vest, shares (in shares) 775,281
Vested and expected, weighted average exercise price (in dollars per share) $ 7
Vested and expected to vest, weighted average remaining contractual term (Year) 4 years 2 months 4 days
Vested and expected to vest, aggregate intrinsic value $ 2,805
Exercisable, shares (in shares) 417,867
Exercisable, weighted average exercise price (in dollars per share) $ 7.56
Exercisable, weighted average remaining contractual term (Year) 2 years 10 months 13 days
Exercisable, aggregate intrinsic value $ 1,277
v3.24.2
Note 6 - Income Taxes (Details Textual) - USD ($)
$ in Thousands
6 Months Ended
Jun. 30, 2024
Jun. 30, 2023
Dec. 31, 2023
Effective Income Tax Rate Reconciliation, Percent 20.90% 29.20%  
Unrecognized Tax Benefits, Ending Balance $ 0   $ 0
Domestic Tax Jurisdiction [Member] | Internal Revenue Service (IRS) [Member]      
Operating Loss Carryforwards     27,200
Tax Credit Carryforward, Amount     $ 2,900
Open Tax Year 2005 2006 2007 2009 2011 2012 2013 2014 2015    
Foreign Tax Jurisdiction [Member]      
Deferred Tax Assets, Valuation Allowance $ 0    
Foreign Tax Jurisdiction [Member] | His Majesty's Revenue and Customs (HMRC) [Member]      
Operating Loss Carryforwards $ 9,800    
State and Local Jurisdiction [Member]      
Open Tax Year 2013 2014 2015 2019 2020 2021 2022    
Foreign Tax Jurisdiction, Other [Member]      
Open Tax Year 2013 2014 2015 2016 2017 2018 2019 2020 2021 2022    
v3.24.2
Note 7 - Operating Leases (Details Textual)
Jun. 30, 2024
Minimum [Member]  
Lessee, Operating Lease, Remaining Lease Term (Year) 1 year
Maximum [Member]  
Lessee, Operating Lease, Remaining Lease Term (Year) 7 years
v3.24.2
Note 7 - Operating Leases - Lease Cost (Details) - USD ($)
$ in Thousands
3 Months Ended 6 Months Ended
Jun. 30, 2024
Jun. 30, 2023
Jun. 30, 2024
Jun. 30, 2023
Operating lease cost $ 268 $ 239 $ 530 $ 480
Variable lease cost 24 29 52 57
Total lease cost $ 292 $ 268 $ 582 $ 537
v3.24.2
Note 7 - Operating Leases - Supplement Cash Flow Information Related to Leases (Details) - USD ($)
$ in Thousands
6 Months Ended
Jun. 30, 2024
Jun. 30, 2023
Operating cash flows from operating leases $ 568 $ 494
Right-of-use assets obtained in exchange for lease liabilities: $ 1,391 $ 310
v3.24.2
Note 7 - Operating Leases - Supplemental Balance Sheet Information Related to Leases (Details) - USD ($)
$ in Thousands
Jun. 30, 2024
Dec. 31, 2023
Weighted-average remaining lease term (years) (Year) 5 years 1 month 6 days 5 years 3 months 18 days
Weighted-average discount rate 6.80% 4.50%
Other Noncurrent Assets [Member]    
Operating lease right-of-use asset $ 4,325 $ 3,589
Accrued Expenses and Other Current Liabilities [Member]    
Current operating lease liability 1,017 894
Other Noncurrent Liabilities [Member]    
Operating lease liability, net of current portion 3,285 2,644
Accrued Expenses and Other Current Liabilites and Other Noncurrent Liabilities [Member]    
Total operating lease liability $ 4,302 $ 3,538
v3.24.2
Note 7 - Operating Leases - Future Minimum Lease Payments (Details) - USD ($)
$ in Thousands
Jun. 30, 2024
Dec. 31, 2023
2024 $ 539  
2025 1,016  
2026 942  
2027 969  
2028 977  
Thereafter 624  
Total lease payments 5,067  
Less: Imputed interest (765)  
Accrued Expenses and Other Current Liabilites and Other Noncurrent Liabilities [Member]    
Present value of remaining lease payments $ 4,302 $ 3,538
v3.24.2
Note 8 - Commitments and Contingencies (Details Textual)
$ in Thousands
6 Months Ended
Jun. 30, 2024
USD ($)
Capital Addition Purchase Commitments [Member]  
Long-Term Purchase Commitment, Amount $ 779
v3.24.2
Note 8 - Commitments and Contingencies - Changes in Product Warranty Liability (Details) - USD ($)
$ in Thousands
6 Months Ended
Jun. 30, 2024
Jun. 30, 2023
Accrued warranty obligations – beginning $ 547 $ 323
Accruals for warranties issued 389 172
Settlements made (147) (62)
Accrued warranty obligations – ending $ 789 $ 433
v3.24.2
Note 9 - Revenue Recognition (Details Textual) - USD ($)
$ in Thousands
3 Months Ended 6 Months Ended
Jun. 30, 2024
Jun. 30, 2024
Dec. 31, 2023
Extended Product Warranty Accrual $ 1,264 $ 1,264 $ 1,407
Accrued Expenses and Other Current Liabilities [Member]      
Extended Product Warranty Accrual, Current 287 287 287
Other Noncurrent Liabilities [Member]      
Extended Product Warranty Accrual, Noncurrent 977 977 $ 1,120
Certain Communications Systems Products [Member]      
Contract with Customer, Liability, Revenue Recognized $ 71 $ 143  
Certain Communications Systems Products [Member] | Maximum [Member]      
Extended Product Warranty, Term   8 years  
v3.24.2
Note 10 - Business Segment Information (Details Textual)
6 Months Ended
Jun. 30, 2024
Number of Operating Segments 2
v3.24.2
Note 10 - Business Segment Information - Segment Activity (Details) - USD ($)
$ in Thousands
3 Months Ended 6 Months Ended
Jun. 30, 2024
Jun. 30, 2023
Jun. 30, 2024
Jun. 30, 2023
Revenues $ 42,983 $ 42,692 $ 84,910 $ 74,608
Segment contribution 3,917 3,665 7,980 3,691
Other income (expense) (71) 1,058 (527) 564
Income tax provision (benefit) (853) (1,375) (1,556) (1,242)
Non-controlling interest (24) (8) (37) (19)
Net loss attributable to Ultralife 2,969 3,340 5,860 2,994
Battery & Energy Products Segment [Member]        
Revenues 36,683 33,861 71,672 62,331
Segment contribution 9,953 7,543 18,939 14,055
Communications Systems Segment [Member]        
Revenues 6,300 8,831 13,238 12,277
Segment contribution 1,610 3,045 4,094 3,969
Corporate Segment [Member]        
Revenues 0 0 0 0
Segment contribution (7,646) (6,923) (15,053) (14,333)
Other income (expense) (71) 1,058 (527) 564
Income tax provision (benefit) (853) (1,375) (1,556) (1,242)
Non-controlling interest $ (24) $ (8) $ (37) $ (19)
v3.24.2
Note 10 - Business Segment Information - Revenue by Business Segment Sector (Details) - USD ($)
$ in Thousands
3 Months Ended 6 Months Ended
Jun. 30, 2024
Jun. 30, 2023
Jun. 30, 2024
Jun. 30, 2023
Revenues $ 42,983 $ 42,692 $ 84,910 $ 74,608
UNITED STATES        
Revenues $ 23,399 $ 21,339 $ 47,860 $ 37,984
Revenue, percentage 54.00% 50.00% 56.00% 51.00%
Non-US [Member]        
Revenues $ 19,584 $ 21,353 $ 37,050 $ 36,624
Revenue, percentage 46.00% 50.00% 44.00% 49.00%
Commercial [Member]        
Revenues $ 27,664 $ 26,950 $ 51,804 $ 49,169
Revenue, percentage 64.00% 63.00% 61.00% 66.00%
Government & Defense [Member]        
Revenues $ 15,319 $ 15,742 $ 33,106 $ 25,439
Revenue, percentage 36.00% 37.00% 39.00% 34.00%
Battery & Energy Products Segment [Member]        
Revenues $ 36,683 $ 33,861 $ 71,672 $ 62,331
Battery & Energy Products Segment [Member] | UNITED STATES        
Revenues 19,412 17,394 39,015 31,162
Battery & Energy Products Segment [Member] | Non-US [Member]        
Revenues 17,271 16,467 32,657 31,169
Battery & Energy Products Segment [Member] | Commercial [Member]        
Revenues 27,664 26,950 51,804 49,169
Battery & Energy Products Segment [Member] | Government & Defense [Member]        
Revenues 9,019 6,911 19,868 13,162
Communications Systems Segment [Member]        
Revenues 6,300 8,831 13,238 12,277
Communications Systems Segment [Member] | UNITED STATES        
Revenues 3,987 3,945 8,845 6,822
Communications Systems Segment [Member] | Non-US [Member]        
Revenues 2,313 4,886 4,393 5,455
Communications Systems Segment [Member] | Commercial [Member]        
Revenues 0 0 0 0
Communications Systems Segment [Member] | Government & Defense [Member]        
Revenues $ 6,300 $ 8,831 $ 13,238 $ 12,277

Ultralife (NASDAQ:ULBI)
Historical Stock Chart
From Oct 2024 to Nov 2024 Click Here for more Ultralife Charts.
Ultralife (NASDAQ:ULBI)
Historical Stock Chart
From Nov 2023 to Nov 2024 Click Here for more Ultralife Charts.